var title_f35_51_36656="Child with fetal alcohol syndrome";
var content_f35_51_36656=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Child with fetal alcohol syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Child with the typical facial features of alcohol syndrome including short palpebral fissures, thin vermilion border of the upper lip, smooth philtrum, and flattened midface.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sadler T. Langman's Medical Embryology, 9th ed, Lippincott Williams &amp; Wilkins, Baltimore, MD&nbsp;2003. Copyright &copy; Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_51_36656=[""].join("\n");
var outline_f35_51_36656=null;
var title_f35_51_36657="Bleeding ileum capsule endoscopy";
var content_f35_51_36657=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F83585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F83585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bleeding in the ileum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Capsule endoscopy image showing bleeding in the ileum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_51_36657=[""].join("\n");
var outline_f35_51_36657=null;
var title_f35_51_36658="Subcorneal pustular dermatosis";
var content_f35_51_36658=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68679%7EDERM%2F78333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68679%7EDERM%2F78333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subcorneal pustular dermatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 260px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Annular pustular dermatosis affecting predominantly flexural areas and causing post-inflammatory pigmentation in a patient with subcorneal pustular dermatosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Samuel Moschella, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subcorneal pustular dermatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 164px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Annular erythematous plaques with superficial pustules are present in the axilla.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_51_36658=[""].join("\n");
var outline_f35_51_36658=null;
var title_f35_51_36659="Fructose, dextrose, and orthophosphoric acid: Patient drug information";
var content_f35_51_36659=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fructose, dextrose, and orthophosphoric acid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/14/10466?source=see_link\">",
"     see \"Fructose, dextrose, and orthophosphoric acid: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F188409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Emetrol&reg; [OTC];",
"     </li>",
"     <li>",
"      Formula EM [OTC];",
"     </li>",
"     <li>",
"      Kalmz [OTC];",
"     </li>",
"     <li>",
"      Nausea Relief [OTC];",
"     </li>",
"     <li>",
"      Nausetrol&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat upset stomach and throwing up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702172",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fructose, dextrose, phosphoric acid, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701063",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to break down fructose.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be refrigerated or poured over ice to make it taste better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694698",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drink any other liquids right before or after taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more than 5 doses in 1 hour unless told to do so by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11740 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-869C284B9E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_51_36659=[""].join("\n");
var outline_f35_51_36659=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188409\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013679\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013678\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013683\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013684\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013686\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013681\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013682\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013687\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013688\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/14/10466?source=related_link\">",
"      Fructose, dextrose, and orthophosphoric acid: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_51_36660="Amifostine: Pediatric drug information";
var content_f35_51_36660=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amifostine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?0/42/678?source=see_link\">",
"    see \"Amifostine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/42/35491?source=see_link\">",
"    see \"Amifostine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ethyol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ethyol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1044992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Cisplatin",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cytoprotective Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1044985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/42/678?source=see_link\">",
"      see \"Amifostine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. (refer to individual protocols):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Limited data available on use in pediatric patients; dosing based on a prior clinical phase I trial and single case reports: 740 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily administered 30 minutes prior to chemotherapy; doses as high as 600 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose administered 15 minutes prior to and 2 hours after chemotherapy (total of 1200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day) have been used in phase I trials in patients treated with ifosfamide, carboplatin, and etoposide chemotherapy; repeat amifostine doses may be required when using a cytotoxic agent with a long half-life or long infusion time",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 910 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily administered 30 minutes prior to chemotherapy; reduce dose to 740 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     in patients who have a higher incidence of hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reduction of moderate to severe xerostomia from radiation of the head and neck: 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily starting 15-30 minutes prior to standard fraction radiation therapy",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F132843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ethyol&reg;: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F132828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1044996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: I.V.: Reconstituted amifostine dose must be further diluted with NS to a final volume of 50 mL (adults) or a final concentration of 5-40 mg/mL (children). Administer amifostine doses &gt;740 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     as an I.V. intermittent infusion over 15 minutes since the 15-minute infusion is better tolerated than a more prolonged infusion. Administer 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     dose as a 3-minute infusion. Amifostine should be interrupted if the blood pressure decreases significantly from baseline or if the patient develops symptoms related to decreased cerebral or cardiovascular perfusion. Patients experiencing decreased blood pressure should receive a rapid infusion of NS and be kept supine or placed in the Trendelenburg position. Amifostine can be restarted if the blood pressure returns to the baseline level.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F132898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, aminophylline, ampicillin, ampicillin/ sulbactam, aztreonam, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, carmustine, cefazolin, cefotaxime, cefotetan, cefoxitin, ceftazidime, cefuroxime, cimetidine, ciprofloxacin, clindamycin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin HCl, dexamethasone sodium phosphate, diphenhydramine, dobutamine, docetaxel, dopamine, doxorubicin HCl, doxycycline, droperidol, enalaprilat, etoposide, famotidine, floxuridine, fluconazole, fludarabine, fluorouracil, furosemide, gallium nitrate, gemcitabine, gentamicin, granisetron, haloperidol lactate, heparin, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydromorphone, idarubicin, ifosfamide, imipenem/cilastatin, leucovorin calcium, lorazepam, magnesium sulfate, mannitol, mechlorethamine, meperidine, mesna, methotrexate, methylprednisolone sodium succinate, metoclopramide, metronidazole, mitomycin, mitoxantrone, morphine, nalbuphine, ondansetron, pemetrexed, piperacillin, potassium chloride, promethazine, ranitidine, sodium bicarbonate, streptozocin, sulfamethoxizole and trimethoprim, teniposide, thiotepa, ticarcillin/clavulanate, tobramycin, vancomycin, vinblastine, vincristine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, amphotericin B, chlorpromazine, cisplatin, ganciclovir, hydroxyzine, minocycline, prochlorperazine edisylate.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1044988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When 500 mg amifostine is reconstituted with 9.7 mL of NS, the resultant solution is stable for 5 hours at room temperature or up to 24 hours if refrigerated; amifostine solutions diluted to 5-40 mg/mL in NS are chemically stable for 5 hours at room temperature or 24 hours if refrigerated; decreased stability in low pH conditions; incompatible with acyclovir, amphotericin B, chlorpromazine, cisplatin, ganciclovir, hydroxyzine, prochlorperazine",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1044995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cytoprotective agent which scavenges free radicals and binds to reactive drug derivatives due to radiation therapy, cisplatin, carboplatin, cyclophosphamide, ifosfamide, carmustine, melphalan, and mechlorethamine to selectively protect normal tissues against toxicity due to these agents; reduction of moderate to severe xerostomia from radiation treatment of the head and neck where the radiation port includes a substantial portion of the parotid glands",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F132900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ethyol&reg; may be confused with ethanol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F132897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypocalcemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Apnea, anaphylactoid reactions, anaphylaxis, arrhythmia, atrial fibrillation, atrial flutter, back pain, bradycardia, cardiac arrest, chest pain, chest tightness, chills, cutaneous eruptions, dizziness, erythema multiforme, exfoliative dermatitis, extrasystoles, dyspnea, fever, flushing, hiccups, hypersensitivity reactions (fever, rash, hypoxia, dyspnea, laryngeal edema), hypertension (transient), hypoxia, malaise, MI, myocardial ischemia, pruritus, rash (mild), renal failure, respiratory arrest, rigors, seizure, sneezing, somnolence, Stevens-Johnson syndrome, supraventricular tachycardia, syncope, tachycardia, toxic epidermal necrolysis, toxoderma, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1044999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amifostine, aminothiol compounds, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1044984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with pre-existing cardiovascular or cerebrovascular conditions such as ischemic heart disease, arrhythmias, CHF, history of stroke or transient ischemic attacks; may cause hypotension; reported incidence is 62% and higher in patients with head and neck cancer, esophageal cancer, nonsmall cell lung cancer, prior neck radiation, or hypercalcemia;  adequately hydrate prior to treatment and keep in a supine position during the infusion. Use special caution in situations where concomitant antihypertensive therapy cannot be interrupted 24 hours prior to starting amifostine or in patients in whom the adverse effects of nausea/vomiting may be more likely to have serious consequences. Infusions &gt;15 minutes are associated with a higher incidence of adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1044983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to limited experience and the possibility of amifostine interference with antineoplastic efficacy, amifostine should not be administered to patients receiving definitive radiation therapy or in settings in which chemotherapy (for malignancies other than ovarian cancer) can produce a significant survival benefit or cure, except in the context of a clinical study. Monitor serum calcium levels in patients at risk of hypocalcemia (eg, those patients receiving multiple doses of amifostine, patients with nephrotic syndrome).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Rare hypersensitivity reactions, including anaphylaxis and allergic reaction, have been reported. Discontinue if allergic reaction occurs; do not rechallenge. Medications for the treatment of hypersensitivity reactions should be available. Serious cutaneous reactions, including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, toxoderma, and exfoliative dermatitis have been reported with amifostine; may be delayed, developing up to weeks after treatment initiation. Cutaneous reactions have been reported more frequently when used as a radioprotectant. Discontinue treatment for severe/serious cutaneous reaction or with fever. Withhold treatment and obtain dermatologic consultation for rash involving lips or mucosa (of unknown etiology outside of radiation port) and for bullous, edematous, or erythematous lesions on hands, feet, or trunk; reinitiate only after careful evaluation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F132837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of Amifostine. Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F132839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2930085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Animal studies have demonstrated embryotoxicity. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1044991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline blood pressure followed by a blood pressure reading every 3-5 minutes during the 15-minute infusion; monitor electrolytes, urinalysis, serum calcium, serum magnesium; monitor I &amp; O; evaluate for cutaneous reactions prior to each dose",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1044982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amifostine is a prodrug that is converted by the plasma membrane-bound enzyme alkaline phosphatase to the active free sulfhydryl compound WR-1065, which is further oxidized to a symmetrical disulfide (WR-33278) or to mixed disulfides. The active drug scavenges free radicals, donates hydrogen ions to free radicals, and binds to active derivatives of antineoplastic agents, thus preventing the alkylation of nucleic acid. Selective protection of normal tissue is demonstrated by:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1) decreased alkaline phosphatase activity in tumor cells,",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2) decreased vascularity of tumors, and",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3) lower pH in tumor tissues due to the predominance of anaerobic metabolism (WR-1065 requires a pH in the range of 6.6-8.2 for uptake into tissues)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1044998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 6.4 L; unmetabolized prodrug is largely confined to the intravascular compartment; active metabolite is distributed into normal tissues with high concentrations in bone marrow, GI mucosa, skin, liver, and salivary glands",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 4%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Amifostine (phosphorylated prodrug) is hydrolyzed by alkaline phosphatase to an active free sulfhydryl compound (WR-1065)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 9.3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 8 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Metabolites excreted in urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adamson PC, Balis FM, Belasco JE, et al, &ldquo;A Phase I Trial of Amifostine (WR-2721) and Melphalan in Children With Refractory Cancer,&rdquo;",
"      <i>",
"       Cancer Res",
"      </i>",
"      , 1995, 55(18): 4069-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/51/36660/abstract-text/7664282/pubmed\" id=\"7664282\" target=\"_blank\">",
"        7664282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fouladi M, Stempak D, Gammon J, et al, &ldquo;Phase I Trial of a Twice-Daily Regimen of Amifostine With Ifosfamide, Carboplatin, and Etoposide Chemotherapy in Children With Refractory Carcinoma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2001, 92(4):914-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/51/36660/abstract-text/11550166 /pubmed\" id=\"11550166 \" target=\"_blank\">",
"        11550166",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuchter LM, &ldquo;Guidelines for the Administration of Amifostine,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1996, 23(4 Suppl 8):40-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/51/36660/abstract-text/8783665/pubmed\" id=\"8783665\" target=\"_blank\">",
"        8783665",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shaw LM, Bonner H, and Lieberman R, &ldquo;Pharmacokinetic Profile of Amifostine,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1996, 23(4 Suppl 8):18-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/51/36660/abstract-text/8783662/pubmed\" id=\"8783662\" target=\"_blank\">",
"        8783662",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13399 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_51_36660=[""].join("\n");
var outline_f35_51_36660=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132861\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132862\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044992\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044985\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132843\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132828\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044996\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132898\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044988\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044995\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132900\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132897\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044999\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044984\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044983\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298731\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132837\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132839\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930085\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044991\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044982\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044998\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13399\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13399|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/42/678?source=related_link\">",
"      Amifostine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/42/35491?source=related_link\">",
"      Amifostine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_51_36661="Use of the signal-averaged electrocardiogram in nonischemic heart disease and cardiac transplantation";
var content_f35_51_36661=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of the signal-averaged electrocardiogram in nonischemic heart disease and cardiac transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/51/36661/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/51/36661/contributors\">",
"     Sanjiv M Narayan, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/51/36661/contributors\">",
"     Michael E Cain, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/51/36661/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/51/36661/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/51/36661/contributors\">",
"     Sharon A Hunt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/51/36661/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/51/36661/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/51/36661/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac death (SCD), predominantly from ventricular tachycardia (VT) or ventricular fibrillation (VF), remains a major public health problem. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .) The signal-averaged electrocardiogram (SAECG) is a noninvasive technique to detect substrate for reentrant arrhythmias such as VT. It has been applied to identify individuals at risk for sudden cardiac death, particularly in the context of coronary artery disease, healed myocardial infarction, and left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/18/4391?source=see_link\">",
"     \"Clinical applications of the signal-averaged electrocardiogram: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with the substrates for VT, slow conduction through myocardium disrupted by inflammation, edema, fibrosis, or scar tissue results in electrical potentials that extend beyond the activation time of normal surrounding myocardium, but which are too small for detection on the surface ECG. The SAECG uses computerized averaging of ECG complexes, obtained during sinus rhythm, to facilitate the detection of these small microvolt level signals, recorded as ventricular late potentials (",
"    <a class=\"graphic graphic_figure graphicRef72380 \" href=\"mobipreview.htm?19/22/19808\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13093?source=see_link\">",
"     \"Technical aspects of the signal-averaged electrocardiogram\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the utility of the SAECG in patients with nonischemic heart disease and in cardiac transplant recipients. The use of the SAECG in patients with ischemic heart disease, arrhythmia, and syncope are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27544?source=see_link\">",
"     \"Use of the signal-averaged electrocardiogram in ischemic heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/39/10872?source=see_link\">",
"     \"Use of the signal-averaged electrocardiogram in arrhythmia evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NONISCHEMIC HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are conflicting on the efficacy of the SAECG in predicting clinical outcome or ventricular arrhythmias in patients with dilated nonischemic cardiomyopathy. Although the SAECG was predictive of total mortality, cardiac death,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arrhythmic events in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/5-7\">",
"     5-7",
"    </a>",
"    ], it was not predictive of outcomes in other series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The predictive value of the SAECG was suggested by a prospective study of 114 patients with nonischemic dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/5\">",
"     5",
"    </a>",
"    ]. Twenty of the 86 patients without bundle branch block had an abnormal SAECG. One-year survival free of ventricular tachycardia (VT) was much lower in those with late potentials on the SAECG (39 percent) as compared to those with a normal SAECG (95 percent) and those with bundle branch block (88 percent). Similarly, a study of 131 patients with dilated cardiomyopathy followed for 54 months found that those with late potentials had an increased risk of all-cause cardiac death (RR 3.3, 95% CI 1.5-7.5) and arrhythmic events (RR 7.2, 95% CI 2.6-19.4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, other large studies of nonischemic dilated cardiomyopathy patients found that the SAECG was not helpful for arrhythmia risk stratification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. For example, a study of 343 patients with idiopathic dilated cardiomyopathy followed for 52 months found that the SAECG was not a predictor of arrhythmia risk or transplantation-free survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/9\">",
"     9",
"    </a>",
"    ]. A study of 137 patients with dilated cardiomyopathy found that microvolt T wave alternans, but not SAECG, was a significant predictor of arrhythmic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/10\">",
"     10",
"    </a>",
"    ]. Some studies have found that SAECG abnormalities are predictive of progressive heart failure in patients with dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some evidence suggests that the SAECG predicts survival in patients with ischemic cardiomyopathy but not in those with nonischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/12\">",
"     12",
"    </a>",
"    ]. One possible explanation for lack of predictive value of the SAECG in some populations of patients with nonischemic cardiomyopathy is that arrhythmias in these patients likely reflect the combined effects of severe structural disease, impaired contractility, high circulating catecholamines, and other dynamic factors. It has been suggested that the process of cardiac dilatation itself may contribute to slow conduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/13\">",
"     13",
"    </a>",
"    ]. This phenomenon may produce late potentials, potentially via myocardial slippage, without additional substrates for arrhythmia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/14\">",
"     14",
"    </a>",
"    ]. Also, arrhythmia etiologies such as enhanced automaticity or triggered activity, rather than slow conduction and reentry, may predominate in patients with dilated cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/17/14615?source=see_link\">",
"     \"Pathogenesis of ventricular arrhythmias in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are insufficient data to recommend the use of the SAECG for risk stratification of patients with nonischemic cardiomyopathy. The 2008 American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    College of",
"    <span class=\"nowrap\">",
"     Cardiology/Heart",
"    </span>",
"    Rhythm Society statement on noninvasive risk stratification techniques noted that use of the SAECG to identify patients at high risk for sudden cardiac death is not adequately supported at this time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DETECTION OF REJECTION AFTER CARDIAC TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac allograft rejection is characterized by myocardial inflammation followed by necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/16\">",
"     16",
"    </a>",
"    ]. Cardiac allograft recipients are at risk for episodes of acute rejection despite current immunosuppressive therapy. Screening for this treatable complication currently depends upon regular endomyocardial biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28040?source=see_link\">",
"     \"Acute cardiac allograft rejection: Diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The SAECG may be sensitive to disruptions in myocardial conduction caused by rejection. Although cardiac transplant rejection may be accompanied by reductions in ECG voltage, bundle branch block and other ECG abnormalities, these indices are insensitive to the less severe rejection that occurs with contemporary immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. However, ECG changes are measurable using more sensitive techniques such as direct intramyocardial measurements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The SAECG has been applied to detect such subtle ECG changes that may accompany grade I to III rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef51982 \" href=\"mobipreview.htm?41/50/42796\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Alterations in results of both time and frequency domain SAECG analyses have been observed during acute transplant rejection. Time-domain analysis of the SAECG demonstrates significant changes in those with rejection although values overlap with those found in those without rejection. For example, in a study of 25 transplant recipients undergoing serial SAECG and endomyocardial biopsy over five months, a reduction in the peak and root mean square (RMS) voltages was observed during rejection. An 11 percent reduction in the RMS voltage of the 70 Hz high pass filtered QRS complex had a sensitivity and specificity for severe rejection of 88 and 78 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/22\">",
"     22",
"    </a>",
"    ]. In general, high pass filtering of the QRS complex at 70 Hz increases the specificity for rejection. Mild rejection episodes were not detected by this method.",
"   </p>",
"   <p>",
"    The utility of frequency domain analysis remains controversial. Some authors found that acute rejection was accompanied by increased spectral magnitudes at 50 to 110 Hz and 70 to 110 Hz with magnitude decreases in the 10 to 30 Hz bandwidth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]; thus, an increased 50-110",
"    <span class=\"nowrap\">",
"     Hz/10-30",
"    </span>",
"    Hz QRS mean ratio was observed among patients with rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/24\">",
"     24",
"    </a>",
"    ]. However, other studies have found frequency analysis to be unhelpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, small studies have found SAECG abnormalities associated with acute cardiac transplant rejection, but the utility of SAECG for diagnosing rejection has not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/26\">",
"     26",
"    </a>",
"    ]. Further evidence and methodologic refinements are required. Emerging implantable devices for intramyocardial electrocardiogram analysis may provide an alternate electrocardiographic method for identifying rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36661/abstract/21,27\">",
"     21,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data are conflicting on the efficacy of SAECG in predicting clinical outcome or ventricular arrhythmias in patients with nonischemic dilated cardiomyopathy.",
"     </li>",
"     <li>",
"      There are insufficient data to recommend the use of the SAECG for risk stratification of patients with nonischemic cardiomyopathy.",
"     </li>",
"     <li>",
"      Although small studies have identified SAECG alterations in patients with cardiac transplant rejection, the utility of SAECG for detection of rejection has not been established.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/1\">",
"      El-Sherif N, Scherlag BJ, Lazzara R, Hope RR. Re-entrant ventricular arrhythmias in the late myocardial infarction period. 1. Conduction characteristics in the infarction zone. Circulation 1977; 55:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/2\">",
"      El-Sherif N, Hope RR, Scherlag BJ, Lazzara R. Re-entrant ventricular arrhythmias in the late myocardial infarction period. 2. Patterns of initiation and termination of re-entry. Circulation 1977; 55:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/3\">",
"      de Bakker JM, van Capelle FJ, Janse MJ, et al. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation 1988; 77:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/4\">",
"      Pogwizd SM, Hoyt RH, Saffitz JE, et al. Reentrant and focal mechanisms underlying ventricular tachycardia in the human heart. Circulation 1992; 86:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/5\">",
"      Mancini DM, Wong KL, Simson MB. Prognostic value of an abnormal signal-averaged electrocardiogram in patients with nonischemic congestive cardiomyopathy. Circulation 1993; 87:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/6\">",
"      Fauchier L, Babuty D, Cosnay P, et al. Long-term prognostic value of time domain analysis of signal-averaged electrocardiography in idiopathic dilated cardiomyopathy. Am J Cardiol 2000; 85:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/7\">",
"      Goedel-Meinen L, Hofmann M, Ryba S, Sch&ouml;mig A. Prognostic value of an abnormal signal-averaged electrocardiogram in patients with nonischemic dilated cardiomyopathy. Am J Cardiol 2001; 87:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/8\">",
"      Brembilla-Perrot B, Terrier de la Chaise A, Jacquemin L, et al. The signal-averaged electrocardiogram is of limited value in patients with bundle branch block and dilated cardiomyopathy in predicting inducible ventricular tachycardia or death. Am J Cardiol 1997; 79:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/9\">",
"      Grimm W, Christ M, Bach J, et al. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation 2003; 108:2883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/10\">",
"      Hohnloser SH, Klingenheben T, Bloomfield D, et al. Usefulness of microvolt T-wave alternans for prediction of ventricular tachyarrhythmic events in patients with dilated cardiomyopathy: results from a prospective observational study. J Am Coll Cardiol 2003; 41:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/11\">",
"      Yi G, Keeling PJ, Goldman JH, et al. Prognostic significance of spectral turbulence analysis of the signal-averaged electrocardiogram in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 1995; 75:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/12\">",
"      Silverman ME, Pressel MD, Brackett JC, et al. Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy. Am J Cardiol 1995; 75:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/13\">",
"      Sung D, Mills RW, Schettler J, et al. Ventricular filling slows epicardial conduction and increases action potential duration in an optical mapping study of the isolated rabbit heart. J Cardiovasc Electrophysiol 2003; 14:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/14\">",
"      Zaman AG, Morris JL, Smyllie JH, Cowan JC. Late potentials and ventricular enlargement after myocardial infarction. A new role for high-resolution electrocardiography? Circulation 1993; 88:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/15\">",
"      Goldberger JJ, Cain ME, Hohnloser SH, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Circulation 2008; 118:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/16\">",
"      Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/17\">",
"      Keren A, Gillis AM, Freedman RA, et al. Heart transplant rejection monitored by signal-averaged electrocardiography in patients receiving cyclosporine. Circulation 1984; 70:I124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/18\">",
"      Cooper DK, Charles RG, Rose AG, et al. Does the electrocardiogram detect early acute heart rejection. J Heart Transplant 1985; 4:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/19\">",
"      Eckart RE, Kolasa MW, Khan NA, et al. Surface electrocardiography and histologic rejection following orthotopic heart transplantation. Ann Noninvasive Electrocardiol 2005; 10:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/20\">",
"      Bonnefoy E, Ninet J, Robin J, et al. Bipolar intramyocardial electrogram from an implanted telemetric pacemaker for the diagnosis of cardiac allograft rejection. Pacing Clin Electrophysiol 1994; 17:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/21\">",
"      Horai T, Fumoto H, Saeed D, et al. Novel implantable device to detect cardiac allograft rejection. Circulation 2009; 120:S185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/22\">",
"      Lacroix D, Kacet S, Savard P, et al. Signal-averaged electrocardiography and detection of heart transplant rejection: comparison of time and frequency domain analyses. J Am Coll Cardiol 1992; 19:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/23\">",
"      Graceffo MA, O'Rourke RA. Cardiac transplant rejection is associated with a decrease in the high-frequency components of the high-resolution, signal-averaged electrocardiogram. Am Heart J 1996; 132:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/24\">",
"      Valentino VA, Ventura HO, Abi-Samra FM, et al. The signal-averaged electrocardiogram in cardiac transplantation. A noninvasive marker of acute allograft rejection. Transplantation 1992; 53:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/25\">",
"      Haberl R, Weber M, Reichenspurner H, et al. Frequency analysis of the surface electrocardiogram for recognition of acute rejection after orthotopic cardiac transplantation in man. Circulation 1987; 76:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/26\">",
"      Signal-averaged electrocardiography. J Am Coll Cardiol 1996; 27:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36661/abstract/27\">",
"      Zupan I, Vrtovec B, Breskvar UD, Gabrijelcic T. Noninvasive monitoring of rejection therapy based on intramyocardial electrograms after orthotopic heart transplantation. Initial experience with 14 cases. Int Immunopharmacol 2005; 5:59.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 987 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-92069A6D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_51_36661=[""].join("\n");
var outline_f35_51_36661=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NONISCHEMIC HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DETECTION OF REJECTION AFTER CARDIAC TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/987\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/987|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/22/19808\" title=\"figure 1\">",
"      Positive SAECG following myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/987|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/50/42796\" title=\"table 1\">",
"      ISHLT cardiac biopsy grades",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28040?source=related_link\">",
"      Acute cardiac allograft rejection: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/18/4391?source=related_link\">",
"      Clinical applications of the signal-averaged electrocardiogram: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/15/18682?source=related_link\">",
"      Evaluation of syncope in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/17/14615?source=related_link\">",
"      Pathogenesis of ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13093?source=related_link\">",
"      Technical aspects of the signal-averaged electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/39/10872?source=related_link\">",
"      Use of the signal-averaged electrocardiogram in arrhythmia evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27544?source=related_link\">",
"      Use of the signal-averaged electrocardiogram in ischemic heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_51_36662="Tetracyclines";
var content_f35_51_36662=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tetracyclines",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/51/36662/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/51/36662/contributors\">",
"     D Byron May, PharmD, BCPS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/51/36662/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/51/36662/contributors\">",
"     David C Hooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/51/36662/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/51/36662/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/51/36662/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chlortetracycline was the first",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    discovered, in 1948. Since then five additional tetracyclines have been isolated or derived (oxytetracycline, tetracycline,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/4/10310?source=see_link\">",
"     demeclocycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    ), but only the last four are available for systemic use in the United States. Of these four agents, doxycycline and minocycline are the most frequently prescribed. Research to find tetracycline analogues lead to the development of the glycylcyclines.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/7/40053?source=see_link\">",
"     Tigecycline",
"    </a>",
"    is the first of this new class of agents and exhibits broad-spectrum antibacterial activity similar to the tetracyclines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    is one of the most active tetracyclines and is the most often used clinically since it possesses many advantages over traditional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    . Doxycycline can be administered twice daily, has both intravenous (IV) and oral (PO) formulations, achieves reasonable concentrations even if administered with food, and is less likely to cause photosensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/2\">",
"     2",
"    </a>",
"    ]. Doxycycline may be an alternative for use in children since it binds calcium to a lesser extent than tetracycline, which can cause tooth discoloration and bony growth retardation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tetracyclines enter the bacterial cell wall in two ways: passive diffusion and an energy-dependent active transport system, which is probably mediated in a pH-dependent fashion. Once inside the cell, tetracyclines bind reversibly to the 30S ribosomal subunit at a position that blocks the binding of the aminoacyl-tRNA to the acceptor site on the mRNA-ribosome complex. Protein synthesis is ultimately inhibited, leading to a bacteriostatic effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to many other antibiotics, tetracyclines are infrequently inactivated biologically or altered chemically by resistant bacteria. Resistance to these agents develops primarily by preventing accumulation of the drug inside the cell either by decreasing influx or increasing efflux. Once resistance develops to one of the drugs in this class, it is typically conferred to all tetracyclines.",
"   </p>",
"   <p>",
"    However, there are differences in resistance among species of bacteria. Resistance genes to tetracyclines often occur on plasmids or other transferable elements such as transposons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/4\">",
"     4",
"    </a>",
"    ]. Bacteria carrying a ribosome protection type of resistance gene produce a cytoplasmic protein that interacts with the ribosomes and allows the ribosomes to proceed with protein synthesis even in the presence of high intracellular levels of the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/7/40053?source=see_link\">",
"     Tigecycline",
"    </a>",
"    has a reduced potential for resistance, as it is not affected by the two major mechanisms of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    resistance: ribosomal protection proteins and efflux pumps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, tigecycline may have activity against tetracycline-resistant organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SPECTRUM OF ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antimicrobial activity of all the tetracyclines is essentially the same although some differences in the relative degree of activity against certain pathogens do exist among the various agents (",
"    <a class=\"graphic graphic_table graphicRef58190 \" href=\"mobipreview.htm?3/32/3596\">",
"     table 1",
"    </a>",
"    ). As an example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    appears to be the most active of the compounds due to its slight increase in lipid solubility.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    follows closely behind.",
"   </p>",
"   <p>",
"    The tetracyclines are considered broad-spectrum bacteriostatic antibiotics that are used to treat infection caused by many aerobic gram-positive and gram-negative bacteria. However, they also have activity against many atypical pathogens, including Rickettsia spp., Borrelia spp., Coxiella burnetii, Treponema spp., Chlamydophila and Chlamydia spp., Mycoplasma pneumoniae, Plasmodium spp., Vibrio cholerae, Vibrio vulnificus, Brucella spp., Calymmatobacterium granulomatis, Leptospira, Borrelia burgdorferi, Borrelia recurrentis, Burkholderia pseudomallei, Mycobacterium marinum, and Entamoeba histolytica. These drugs have little activity against fungi and viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Against N. gonorrhoeae, the 2006 Gonococcal Isolate Surveillance Project (GISP) report shows that 25.6 percent of isolates collected in 2006 were resistant to penicillin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , or some combination of those antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/10\">",
"     10",
"    </a>",
"    ]. Therefore, use of tetracyclines for the treatment of N. gonorrhoeae in the US is NOT recommended by the CDC.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    is effective for patients with nongonococcal urethritis caused by Chlamydia trachomatis; however, recurrent urethritis in patients previously treated with doxycycline may be the result of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    -resistant U. urealyticum. Doxycycline is an alternative agent in the treatment of genital Chlamydial infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/7/40053?source=see_link\">",
"     Tigecycline",
"    </a>",
"    has a broader spectrum of activity when compared to the tetracyclines. Tigecycline has activity against gram-positive pathogens including: Enterococcus spp., vancomycin-resistant enterococci (VRE), Listeria, Streptococcus spp., both methicillin-susceptible and -resistant S. aureus, and S. epidermidis. Its gram-negative activity includes: Acinetobacter baumannii, Citrobacter spp., Enterobacter spp., Escherichia coli, Klebsiella spp., Pasteurella multocida, Serratia marcescens, and Stenotrophomonas maltophilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHARMACODYNAMICS/PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In animal studies, the",
"    <span class=\"nowrap\">",
"     pharmacokinetic/pharmacodynamic",
"    </span>",
"    parameter that most closely correlates with the efficacy of tetracyclines is the 24 hour ratio of the area under the concentration-versus-time curve (AUC) to the minimum inhibitory concentration (MIC). After exposure of Staphylococcus aureus to the tetracyclines at five times the MIC for two hours, a post-antibiotic effect lasting for three hours has been observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Combination of tetracyclines and penicillins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A deleterious effect was observed for the combination of a static and cidal antibiotic when chlortetracycline and penicillin were used together for the treatment of pneumococcal meningitis. The combination of the two drugs was inferior to penicillin alone.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     Tetracycline",
"    </a>",
"    administered with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    may result in diminished bactericidal activity of the penicillin. Thus, combinations of tetracyclines and penicillins should be avoided, if possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Absorption of the tetracyclines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absorption of tetracyclines occurs primarily in the proximal small intestine and the stomach. The bioavailability of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    approaches 95 percent (with or without food), with peak serum concentrations seen one to three hours after the dose. By contrast, the bioavailability of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    is reduced by 50 percent if it is taken with food. The absorption of all tetracyclines can be decreased with the concomitant administration of multivalent cations (ie, aluminum, calcium, iron, magnesium). These cations chelate with the tetracyclines impairing their absorption. Concurrent administration of products containing divalent or trivalent cations should be avoided with all tetracyclines with the possible exception of doxycycline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Serum concentrations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maximum serum concentration after an intravenous dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    occurs within 30 minutes; after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    , within one hour. Peak concentrations of doxycycline range from 1.5 to 2.5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    after a dose of 200 mg orally and 4 to 10",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for the same dose administered intravenously. Doxycycline has an apparent volume of distribution of 50 liters and is 90 percent protein bound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, tetracyclines penetrate into tissues and body fluids fairly well. Among the following agents, the degree of tissue penetration correlates to lipid solubility:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    &gt;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    &gt;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , therapeutic concentrations have been found in the aqueous humour, CSF (11 to 56 percent of serum concentrations), peritoneal fluid, tears, lungs, sinuses, digestive and biliary tracts, kidney, liver, and prostate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Doxycycline also distributes into the bone, fat, and muscle at concentrations below plasma levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     Tetracycline",
"    </a>",
"    distributes well into ascitic fluid, bile, CNS (10 to 26 percent), sinuses, pleural and synovial fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     Minocycline",
"    </a>",
"    has been found in therapeutic concentrations in the aqueous humor, bile, duodenum, fallopian",
"    <span class=\"nowrap\">",
"     tubes/ovaries,",
"    </span>",
"    liver, lung, sinuses, saliva, sputum, tears, and thyroid gland. Minocycline distributes in lower concentrations to the bladder, breast, lymph nodes, prostate, and skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/7/40053?source=see_link\">",
"     Tigecycline",
"    </a>",
"    distributes well into the bile, CSF, and lung. Animal data demonstrate that tigecycline distributes well into bone, bone marrow, spleen, and thyroid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/15,17\">",
"     15,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, all the tetracyclines cross the placenta and accumulate in the bone and teeth of the fetus. The tetracyclines are also excreted in breast milk, although complexation with calcium in breast milk limits availability to the breast-fed infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Routes of elimination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routes of elimination differ among the tetracyclines. The primary route of elimination for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    is the kidney via glomerular filtration.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    is primarily eliminated in the intestinal tract, with up to 90 percent of the dose excreted in the feces. Approximately 20 percent of a doxycycline dose is eliminated by glomerular filtration.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/7/40053?source=see_link\">",
"     Tigecycline",
"    </a>",
"    is eliminated through the feces as unchanged drug.",
"   </p>",
"   <p>",
"    Dose adjustment is not necessary for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    in patients with renal dysfunction, and thus, these are the preferred tetracyclines in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/13\">",
"     13",
"    </a>",
"    ]. Dose adjustment is only required in severe hepatic dysfunction for doxycycline and tigecycline (maintenance dose 25 mg IV every 12 hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/6\">",
"     6",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     Minocycline",
"    </a>",
"    is metabolized in the liver to at least six inactive metabolites. Only 4 to 9 percent of minocycline is excreted via the kidneys, and fecal concentrations are also minimal. No accumulation of minocycline is seen with hepatic failure. Similar to doxycycline, food has little effect on the absorption of minocycline. The tetracyclines are minimally removed by hemodialysis, peritoneal dialysis, or hemofiltration; therefore, dose adjustments are not necessary in these situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pregnant or breastfeeding women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetracyclines can cause fetal toxicity when given to pregnant women. For certain infections, the potential risks may be offset by the benefits. However, tetracyclines should generally",
"    <strong>",
"     not",
"    </strong>",
"    be used in pregnant women or children under the age of eight years unless other appropriate drugs are ineffective or contraindicated.",
"   </p>",
"   <p>",
"    Tetracyclines cross the placenta and achieve concentrations in umbilical-cord plasma and amniotic fluid of 60 and 20 percent, respectively, of levels in the maternal circulation. This can cause accumulation in fetal bone and teeth. Tetracyclines are found in high concentrations in human breast milk, but concentrations are very low in breast-fed infants, which is probably a reflection of chelation by calcium in breast milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;These agents, with the possible exception of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    , should generally not be used in patients with end-stage renal disease (",
"    <a class=\"graphic graphic_table graphicRef80309 \" href=\"mobipreview.htm?14/23/14715\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ADVERSE REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetracyclines are generally safe drugs, but some adverse effects can occur.",
"   </p>",
"   <p>",
"    The following provides a brief summary of some of the major adverse effects associated with tetracyclines. These issues are discussed in detail separately. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     \"Tetracycline: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/10/36005?source=see_link\">",
"     \"Doxycycline: Patient drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/4/10310?source=see_link\">",
"     \"Demeclocycline: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     \"Minocycline: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dose-related gastrointestinal side effects are the most common complaint in patients taking oral tetracyclines and intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/1\">",
"     1",
"    </a>",
"    ]. These include abdominal discomfort, epigastric pain, nausea, vomiting and anorexia. Food may decrease these symptoms but also may decrease the absorption of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    by 50 percent. Food does not affect the absorption of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Tetracyclines may alter gut flora to cause large bulky stools and diarrhea. Diarrhea usually subsides once the agent is stopped. A patient with continued diarrhea, fever, and a rising white blood count should be evaluated for antibiotic associated diarrhea caused by Clostridium difficile. Esophageal ulcerations and strictures have been reported with tetracyclines but can be prevented by taking the drugs with plenty of water and not before bedtime. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Allergic and skin reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity reactions can occur with tetracyclines but are uncommon. If a patient is allergic to one",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    , they should be considered allergic to all. Photosensitivity reactions can occur, ranging from a red rash to blistering on areas exposed to the sun. These reactions are most common with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/4/10310?source=see_link\">",
"     demeclocycline",
"    </a>",
"    but can occur with all analogues. Photosensitivity can be decreased by avoiding direct sunlight or wearing protective clothing with sunscreen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Teeth and bone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetracyclines can cause a brown to yellow discoloration of the teeth in children under the age of eight that is sometimes associated with hypoplasia of the enamel. The darkening effect on the permanent teeth appears to be dose related and does not occur in adults. These agents generally should be avoided in children under the age of eight; however if they must be used,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    may be the preferred agent. Tetracyclines may also deposit in the bone likely due to chelate formation with calcium, thus adding another reason to avoid these agents in children with developing bone formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Liver and renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatotoxicity with tetracyclines is rare but can be fatal. This occurs more commonly with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    and less often with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tetracyclines inhibit protein synthesis and may exacerbate preexisting renal failure by increasing the azotemia from amino acid metabolism.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/4/10310?source=see_link\">",
"     Demeclocycline",
"    </a>",
"    can cause a nephrogenic diabetes insipidus, a side effect that is used therapeutically to treat the syndrome of inappropriate antidiuretic hormone secretion (SIADH). The use of outdated tetracyclines has been associated with a reversible Fanconi-like syndrome and renal tubular acidosis; however, current formulations, which do not contain citric acid as an excipient, have virtually eliminated this possibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17306?source=see_link\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Miscellaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Jarisch-Herxheimer type reaction (JHR) has occurred in patients being treated for spirochetal infections. Effects include fever, chills, headache, malaise, muscle aches, leukocytosis, and exacerbation of cutaneous lesions. The JHR occurs in 75 to 80 percent of those treated for syphilis, 54 percent of those treated for tick-borne relapsing fever, and 82 percent of those treated for louse-borne relapsing fever. Prevention of the JHR in patients is of limited value; the best results are with the use of tumor necrosis factor (TNF) antibodies and steroids. Pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or meptazinol may reduce the symptoms and duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vertigo has been associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    and appears to be dose-related. More common in women than men, this may appear during the second or third day of therapy and usually resolves in one to two days after discontinuing the drug. Complaints consist of dizziness, ataxia, nausea, vomiting, and tinnitus.",
"   </p>",
"   <p>",
"    Hematologic effects are very uncommon but may include hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia. Other, less common reactions, include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    -induced lupus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/20-22\">",
"     20-22",
"    </a>",
"    ] and pericardial effusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nausea and vomiting have been reported with increased frequency with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    (30 and 20 percent) compared to tetracyclines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36662/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tetracyclines can interact with a variety of other drugs. These interactions are discussed separately. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     \"Tetracycline: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/10/36005?source=see_link\">",
"     \"Doxycycline: Patient drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/4/10310?source=see_link\">",
"     \"Demeclocycline: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     \"Minocycline: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/7/40053?source=see_link\">",
"     \"Tigecycline: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9761634\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tetracyclines inhibit bacterial protein synthesis by binding reversibly to the 30S ribosomal subunit. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decreased accumulation of drug within bacteria leads to resistance; drug uptake is affected by decreasing influx or increasing efflux. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The tetracyclines are considered broad-spectrum bacteriostatic antibiotics with activity against many aerobic gram-positive and gram-negative bacteria and atypical pathogens, such as mycoplasma and chlamydia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Spectrum of activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Absorption of tetracyclines occurs primarily in the proximal small intestine and the stomach with good distribution into tissues and body fluids. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pharmacodynamics/pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tetracyclines should generally not be used in pregnant women or children under the age of eight years unless other appropriate drugs are ineffective or contraindicated. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Special populations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tetracyclines are generally safe; the most common adverse events are related to gastrointestinal symptoms (eg, epigastric discomfort and nausea). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Adverse reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/1\">",
"      Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis 2006; 43:518.",
"     </a>",
"    </li>",
"    <li>",
"     Perdue, BE, Standiford, HC. Tetracyclines. In: Antimicrobial Therapy and Vaccines, Yu, VL, Merigan, TC, Barriere, SL (Eds), Williams and Wilkins, Baltimore 1999. p.981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/3\">",
"      Schnappinger D, Hillen W. Tetracyclines: antibiotic action, uptake, and resistance mechanisms. Arch Microbiol 1996; 165:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/4\">",
"      Speer BS, Shoemaker NB, Salyers AA. Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance. Clin Microbiol Rev 1992; 5:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/5\">",
"      Roberts MC. Tetracycline therapy: update. Clin Infect Dis 2003; 36:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/6\">",
"      Tigecycline (tygacil). Med Lett Drugs Ther 2005; 47:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/7\">",
"      Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/8\">",
"      Wyeth antibiotic Tygacil approved for broad-spectrum, early use. \"The Pink Sheet\" 2005; 67:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/9\">",
"      Klein NC, Cunha BA. Tetracyclines. Med Clin North Am 1995; 79:789.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2006. Atlanta, GA: U.S. Department of Health and Human Services, November 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Nonfatal, unintentional medication exposures among young children--United States, 2001-2003. MMWR Morb Mortal Wkly Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/12\">",
"      Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/13\">",
"      Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988; 15:355.",
"     </a>",
"    </li>",
"    <li>",
"     Mandell, GL, Bennett, JE, Dolin, R, et al. Principles and Practices of Infectious Diseases, 6th ed, Churchill Livingstone, Philadelphia 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/15\">",
"      Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 2006; 58:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/16\">",
"      Yim CW, Flynn NM, Fitzgerald FT. Penetration of oral doxycycline into the cerebrospinal fluid of patients with latent or neurosyphilis. Antimicrob Agents Chemother 1985; 28:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/17\">",
"      MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother 2008; 62 Suppl 1:i11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/18\">",
"      Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. J Clin Pharm Ther 2007; 32:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/19\">",
"      Pound MW, May DB. Proposed mechanisms and preventative options of Jarisch-Herxheimer reactions. J Clin Pharm Ther 2005; 30:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/20\">",
"      Schlienger RG, Bircher AJ, Meier CR. Minocycline-induced lupus. A systematic review. Dermatology 2000; 200:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/21\">",
"      Colmegna I, Perandones CE, Chaves JG. Minocycline induced lupus and autoimmune hepatitis. J Rheumatol 2000; 27:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/22\">",
"      Lawson TM, Amos N, Bulgen D, Williams BD. Minocycline-induced lupus: clinical features and response to rechallenge. Rheumatology (Oxford) 2001; 40:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36662/abstract/23\">",
"      Christe C, Ricou F, Stoller R, Vogt N. Minocycline-induced pericardial effusion. Ann Pharmacother 2000; 34:875.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 494 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-6720EAAD2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_51_36662=[""].join("\n");
var outline_f35_51_36662=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9761634\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SPECTRUM OF ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHARMACODYNAMICS/PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Combination of tetracyclines and penicillins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Absorption of the tetracyclines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Serum concentrations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Routes of elimination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pregnant or breastfeeding women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ADVERSE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Allergic and skin reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Teeth and bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Liver and renal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Miscellaneous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9761634\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/494\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/494|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/32/3596\" title=\"table 1\">",
"      Spectrum of activity of the tetracyclines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/23/14715\" title=\"table 2\">",
"      Dosing and administration of tetracyclines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/4/10310?source=related_link\">",
"      Demeclocycline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/10/36005?source=related_link\">",
"      Doxycycline: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=related_link\">",
"      Minocycline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=related_link\">",
"      Tetracycline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/7/40053?source=related_link\">",
"      Tigecycline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_51_36663="Paliperidone: Pediatric drug information";
var content_f35_51_36663=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Paliperidone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44728?source=see_link\">",
"    see \"Paliperidone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/42/3750?source=see_link\">",
"    see \"Paliperidone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3981432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Invega&reg;;",
"     </li>",
"     <li>",
"      Invega&reg; Sustenna&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5941023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Invega&reg;;",
"     </li>",
"     <li>",
"      Invega&reg; Sustenna&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F15513469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsychotic Agent, Atypical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsychotic Agent, Benzisoxazole",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F15513477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44728?source=see_link\">",
"      see \"Paliperidone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Schizophrenia:",
"     </b>",
"     Children &ge;12 and Adolescents: Oral: 3 mg once daily; titration not necessary; if after clinical assessment a dosage increase is required, may increase dose in 3 mg/day increments at least every 5 days; maximum daily dose is weight dependent:  &lt;51 kg: 6 mg/",
"     <b>",
"      day",
"     </b>",
"     ; &ge;51 kg: 12 mg/",
"     <b>",
"      day",
"     </b>",
"     ;",
"     <b>",
"      Note:",
"     </b>",
"     During adolescent clinical trials, higher doses were not associated with greater efficacy, but increased risk of adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Irritability associated with autistic disorder:",
"     </b>",
"     Limited data available: Children &ge;12 years and Adolescents: Oral: Initial: 3 mg once daily; titrate on a weekly basis in 3 mg/day increments until clinical response or intolerance; maximum daily dose: 12 mg/",
"     <b>",
"      day",
"     </b>",
"     . Dosing based on an open-label trial of 25 patients (mean age: 15.3 years; age range: 12-21 years); therapeutic response was reported in 84% of patients at a mean final dose: 7.1 mg/day (Stigler, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Schizoaffective disorder, schizophrenia:",
"     </b>",
"     Oral: Usual: 6 mg once daily in the morning; titration not required, though some may benefit from higher or lower doses. If dose exceeding 6 mg/day, increases of 3 mg/day are recommended no more frequently than every 4 days in schizoaffective disorder or every 5 days in schizophrenia, up to a maximum of 12 mg/day. Some patients may require only 3 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Schizophrenia:",
"     </b>",
"     I.M.:",
"     <b>",
"      Note:",
"     </b>",
"     Prior to initiation of I.M therapy, tolerability should be established with oral paliperidone or oral risperidone. Previous oral antipsychotics can be discontinued at the time of initiation of I.M. therapy.",
"     <b>",
"      Dosing based on paliperidone palmitate.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Initiation of therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Initial: 234 mg on treatment day 1 followed by 156 mg 1 week later. The second dose may be administered 2 days before or after the weekly timepoint.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Maintenance: Following the 1-week initiation regimen, begin a maintenance dose of 117 mg every month. Some patients may benefit from higher or lower monthly maintenance doses (monthly maintenance dosage range: 39-234 mg). The monthly maintenance dose may be administered 7 days before or after the monthly timepoint.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Conversion from oral paliperidone to I.M paliperidone: Initiate I.M. therapy as described using the 1-week initiation regimen. Patients previously stabilized on oral doses can expect similar steady state exposure during maintenance treatment with I.M. therapy using the following conversion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Oral extended release dose of 12 mg, then I.M. maintenance dose of 234 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Oral extended release dose of 6 mg, then I.M. maintenance dose of 117 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Oral extended release dose of 3 mg, then I.M. maintenance dose of 39-78 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Switching from other long acting injectable antipsychotics to I.M. paliperidone: Initiate I.M. paliperidone in the place of the next scheduled injection and continue at monthly intervals. The 1-week initiation regimen is not required in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Dosage adjustments: Adjustments may be made monthly (full effect from adjustments may not be seen for several months)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Missed doses:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If &lt;6 weeks has elapsed since the last monthly injection: Administer the missed dose as soon as possible and continue therapy at monthly intervals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If &gt;6 weeks and &le;6 months has elapsed since the last monthly injection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     If the maintenance dose was &lt;234 mg: Administer the same dose the patient was previously stabilized on as soon as possible, followed by a second equivalent dose 1 week later, then resume maintenance dose at monthly intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     If the maintenance dose was 234 mg: Administer a 156 mg dose as soon as possible, followed by a second dose of 156 mg 1 week later, then resume maintenance dose at monthly intervals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If &gt;6 months has elapsed since last monthly maintenance injection: Therapy must be reinitiated following dosing recommendations for initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years and Adolescents:  There are no dosing adjustments provided in manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-79 mL/minute: Initial: 3 mg once daily; maximum dose: 6 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-49 mL/minute: Initial: 1.5 mg once daily; maximum dose: 3 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Use not recommended; not studied in this population",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-79 mL/minute: Initiation of therapy: 156 mg on treatment day 1, followed by 117 mg 1 week later, followed by a maintenance dose of 78 mg every month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Use not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment hepatic impairment:",
"     </b>",
"     Oral, I.M.: No adjustment necessary for mild to moderate (Child-Pugh class A or B) impairment. Not studied in severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3982430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension, extended release, as palmitate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Invega&reg; Sustenna&reg;: 39 mg/0.25 mL (0.25 mL); 78 mg/0.5 mL (0.5 mL); 117 mg/0.75 mL (0.75 mL); 156 mg/mL (1 mL); 234 mg/1.5 mL (1.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Invega&reg;: 1.5 mg, 3 mg, 6 mg, 9 mg [osmotic controlled release]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3981434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15513478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer in the morning without regard to meals; swallow extended release tablets whole with liquids; do not crush, chew, or divide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M. (Invega&reg; Sustenna&trade;): Shake prefilled syringe for at least 10 seconds to ensure a homogenous suspension; administer I.M. as a single injection (do not divide doses) injection should be slow and deep into the muscle. When initiating therapy, the deltoid muscle should be used for the first two doses to rapidly attain therapeutic concentrations (see manufacturer labeling for specific needle length/gauge).  Monthly maintenance doses can be administered in either the deltoid muscle or upper, outer quadrant of gluteal muscle; may alternate injection sites.  Do not administer I.V. or subQ; avoid inadvertent injection into vasculature.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F15513474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Store at &le;25&deg;C (77&deg;F); protect from moisture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15513470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Treatment of schizophrenia (FDA approved in ages &ge;12 years and adults); treatment of schizoaffective disorder as monotherapy or adjunctive therapy to mood stabilizers and/or antidepressants (FDA approved in adults); has also been used for treatment of irritability associated with autistic disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Treatment of schizophrenia (acute and maintenance) (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14087817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F3982388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Bundle branch block, orthostatic hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Agitation, akathisia, anxiety, dizziness, dystonia, dysarthria, EPS, fatigue, headache, insomnia, lethargy, parkinsonism, sleep disorder, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Amenorrhea, galactorrhea, gynecomastia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain, appetite increased, constipation, diarrhea, dyspepsia, nausea, salivation increased, tongue paralysis, tongue swelling, toothache, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: I.M. formulation: Injection site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Back pain, dyskinesia, extremity pain, hyperkinesia, myalgia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Cough, nasopharyngitis, rhinitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Agranulocytosis, ALT increased, amenorrhea, appetite decreased, anaphylactic reaction, angioedema, arrhythmia, arthralgia, aspiration pneumonia, AV block (first degree), blurred vision, bradycardia, breast abnormalities (includes discharge, engorgement, pain, tenderness), cerebrovascular accident, drooling, edema, erectile dysfunction, epistaxis, fatigue, flatulence, galactorrhea, gynecomastia, hyper-/hypotension, hyperprolactinemia, hypertonia, intestinal obstruction, ischemia, lethargy, leukopenia, menstrual irregularities, nasal congestion, neuroleptic malignant syndrome, neutropenia, nightmares, oculogyric crisis, palpitation, peripheral edema, pharyngolaryngeal pain (dose dependent), postural dizziness, postural orthostatic tachycardia syndrome, priapism, pruritus, psychomotor hyperactivity, QT",
"     <sub>",
"      c",
"     </sub>",
"     -interval prolongation, rash, restlessness, retrograde ejaculation, seizure, sexual dysfunction, stiffness, suicidal ideation, syncope, thrombotic thrombocytopenic purpura (TTP), tongue swelling, transient ischemic attack, urinary incontinence, urinary retention, urinary tract infection, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15513471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to paliperidone, risperidone, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F15513490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment; clearance is reduced (%) based on severity of impairment: Mild (32%), moderate (64%), and severe (71%); dosage adjustment required. Use with caution in patients with severe hepatic impairment, use has not been studied; in patients with mild to moderate hepatic impairment, no dosage adjustment is required. Use with caution in patients with breast cancer or other prolactin-dependent tumors; paliperidone elevates prolactin levels to a similar degree as risperidone, a drug known to elevate prolactin to a greater degree than other antipsychotic agents; high levels of prolactin may reduce pituitary gonadotropin secretion; galactorrhea, amenorrhea, gynecomastia, impotence, decreased bone density may occur. Use with caution in children and adolescents; adverse effects due to elevated prolactin levels have been observed; long-term effects on growth or sexual maturation have not been evaluated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Paliperidone may cause a higher than normal weight gain in children and adolescents; monitor growth (including weight, height, BMI, and waist circumference) in pediatric patients receiving paliperidone; in adolescent trials, &le;19% of patients experienced a weight gain of &ge;7%; monitor weight and compare to standard growth curves. Paliperidone may cause increases in metabolic indices (eg, serum cholesterol, triglycerides). Biannual monitoring of cardiometabolic indices after the first 3 months of therapy is suggested for atypical antipsychotics (Correll, 2009).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with seizure disorders or patients with conditions that lower seizure threshold; seizures have been rarely reported. Use with caution in patients with  Parkinson's disease, in suicidal patients, and in those at risk of aspiration pneumonia (esophageal dysmotility and aspiration have been associated with antipsychotic agents). May cause orthostatic hypotension with resultant dizziness, tachycardia, or syncope (especially during initial dose titration); use with caution in patients with cardiovascular disease (heart failure, past MI, or myocardia ischemia), cerebrovascular disease, dehydration, hypovolemia, or other conditions which may predispose patients to hypotension; may cause hypotension when used with antihypertensive agents. May cause somnolence (dose-related), priapism (rarely), alteration of temperature regulation (use with caution in patients exposed to temperature extremes). Paliperidone exhibits antiemetic effects and may mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Adolescents may experience a higher frequency of certain adverse effects than adults, particularly akathisia (4% to 17% vs 1% to 10%; dose-dependent), somnolence (9% to 26% vs 1% to 12%), vomiting (&le;11% vs 2% to 5%). Adolescents may experience some adverse effects not reported in adults, including amenorrhea, blurred vision, galactorrhea, gynecomastia, and tongue swelling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Extended release tablets: Use is not recommended in patients with pre-existing severe gastrointestinal narrowing disorders (esophageal  motility disorders, small bowel inflammatory disease, \"short gut\" syndrome, history of peritonitis, cystic fibrosis, chronic intestinal pseudoobstruction, or Meckel's diverticulum); formulation consists of drug within a nonabsorbable shell; following drug release and absorption, the shell is expelled in the stool; patients with upper GI tract alterations in transit time may have increased or decreased bioavailability of paliperidone.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Paliperidone is an active metabolite of risperidone; concomitant use with risperidone has not been studied; pharmacokinetic data suggests additional paliperidone exposure and corresponding effects.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15513472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     May cause neuroleptic malignant syndrome (symptoms include hyperpyrexia, altered mental status, muscle rigidity, autonomic instability, acute renal failure, rhabdomyolysis, and elevated CPK). May cause extrapyramidal reactions, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is low relative to other neuroleptics, and is dose-dependent; to decrease risk of tardive dyskinesia, use smallest dose and shortest duration possible; evaluate continued need periodically; risk of dystonia is increased with the use of high potency and higher doses of conventional antipsychotics and in males and younger patients; occurring in up to 18% of children). May cause hyperglycemia, which may be severe and include potentially fatal ketoacidosis or hyperosmolar coma; use with caution and monitor glucose closely in patients with diabetes mellitus (or with risk factors such as family history or obesity); measure fasting blood glucose at the beginning of therapy and periodically during therapy in these patients; monitor for symptoms of hyperglycemia in all patients treated with  paliperidone; measure fasting blood glucose in patients who develop symptoms.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May alter cardiac conduction and prolong the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics. Risk may be increased by conditions or concomitant medications which cause bradycardia, hypokalemia, and/or hypomagnesemia. Avoid use in combination with QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging drugs and in patients with congenital long QT syndrome or patients with history of cardiac arrhythmia.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     An increased risk of death has been reported with the use of antipsychotics in elderly patients with dementia-related psychosis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most deaths seemed to be cardiovascular (eg, sudden death, heart failure) or infectious (eg, pneumonia) in nature. An increased incidence of cerebrovascular adverse events (eg, transient ischemic attack, stroke), including fatalities, has been reported in placebo-controlled trials of risperidone (paliperidone is the primary active metabolite of risperidone) in elderly patients with dementia-related psychosis. Paliperidone is not approved for the treatment of patients with dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9838448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3982393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): Antipsychotics (Atypical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Paliperidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Paliperidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May decrease the metabolism of Paliperidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: May enhance the adverse/toxic effect of Paliperidone. Management: Additive paliperidone exposure is expected with this combination.  Consider using an alternative combination when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Paliperidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F15513473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration of extended release tablet with high-fat/high caloric meal increases the mean maximum serum concentration and AUC by 60% and 54%, respectively, compared to fasting. During clinical trials, paliperidone was administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3982378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3982379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Antipsychotic use during the third trimester of pregnancy has a risk for extrapyramidal symptoms (EPS) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor. These effects may be self-limiting and allow recovery within hours or days with no specific treatment, or they may be severe requiring prolonged hospitalization. Paliperidone may cause hyperprolactinemia, which may decrease reproductive function in both males and females. Paliperidone is the active metabolite of risperidone; refer to Risperidone monograph for additional information.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The ACOG recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy is limited and routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to a typical antipsychotic that the fetus has not yet been exposed to; consider risk:benefit (ACOG, 2008).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll women 18-45 years of age exposed to paliperidone during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or file://www.womensmentalhealth.org/pregnancyregistry).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15513479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure (including orthostatic) and heart rate, particularly during dosage titration; mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms; growth, BMI, waist circumference, and weight (in adults, weight should be assessed prior to treatment, at 4 weeks, 8 weeks, 12 weeks, and then at quarterly intervals; consider titrating to a different antipsychotic agent for a weight gain &ge;5% of the initial weight); CBC with differential; liver enzymes in children (especially obese children or those who are rapidly gaining weight while receiving therapy); lipid profile; fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     (prior to treatment, at 3 months, then annually); prolactin serum concentrations",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15513475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Paliperidone is a benzisoxazole atypical antipsychotic; highly potent serotonin and dopamine receptor antagonist;  the primary active metabolite of risperidone. The addition of serotonin antagonism to dopamine antagonism (classic neuroleptic mechanism) is thought to improve negative symptoms of psychoses and reduce the incidence of extrapyramidal side effects. Alpha",
"     <sub>",
"      1",
"     </sub>",
"     , alpha",
"     <sub>",
"      2",
"     </sub>",
"     adrenergic, and histaminergic receptors are also antagonized at varying degrees. Similar to risperidone, paliperidone demonstrates high affinity to &alpha;",
"     <sub>",
"      1",
"     </sub>",
"     , D",
"     <sub>",
"      2",
"     </sub>",
"     , H",
"     <sub>",
"      1",
"     </sub>",
"     , and 5-HT",
"     <sub>",
"      2C",
"     </sub>",
"     receptors, and low affinity for muscarinic and 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     receptors. In contrast to risperidone, paliperidone displays nearly 10-fold lower affinity for &alpha;",
"     <sub>",
"      2",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      2A",
"     </sub>",
"     receptors, and nearly three- to fivefold less affinity for 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      1D",
"     </sub>",
"     , respectively.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15513476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Pharmacokinetic parameters in adolescent patients weighing &gt;51 kg were similar to adults; an increased drug exposure (23%) was observed in adolescent patient weighing &lt;51 kg compared to adults and was not considered clinically significant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: Slow release (begins on day 1 and continues up to 126 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution, apparent V",
"     <sub>",
"      d",
"     </sub>",
"     : 391-487 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 74%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2D6 and 3A4 (limited role in elimination); minor metabolism (&lt;10% each) via dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 28%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 23 hours; prolonged with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;80 mL/minute): 24-51 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M. (single dose): Range: 25-49 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: ~24 hours; I.M.:13 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (80%; 59% as unchanged drug);  feces (11%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F15513480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/42/3750?source=see_link\">",
"      see \"Paliperidone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not chew, crush, or break tablet; swallow whole with liquids. It may take several weeks to achieve desired results. Maintain adequate hydration. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; may cause postural hypotension, especially during initial dose titration (use caution when changing position from lying or sitting to standing).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Do not  use other medications, nonprescription medications, and herbal or natural products without checking with prescriber or pharmacist; avoid alcohol and the herbal medicine, St John's wort. Report persistent CNS effects (eg, trembling fingers, altered gait or balance, excessive sedation, seizures, unusual muscle or skeletal movements), rapid heartbeat, palpitations, severe dizziness, fainting, swelling or pain in breasts (male and female), altered menstrual pattern, changes in urinary patterns, vision changes, skin rash, difficulty breathing, or worsening of condition to physician.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F15513481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term usefulness of paliperidone should be periodically re-evaluated in patients receiving the drug for extended periods of time. Invega&reg; is an extended release tablet based on the OROS&reg; osmotic delivery system. Water from the GI tract enters through a semipermeable membrane coating the tablet, solubilizing the drug into a gelatinous form which, through hydrophilic expansion, is then expelled through laser-drilled holes in the coating.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Correll CU, Manu P, Olshanskiy V, et al, \"Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(16):1765-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/51/36663/abstract-text/19861668/pubmed\" id=\"19861668\" target=\"_blank\">",
"        19861668",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh J, Robb A, Vijapurkar U, et al, \"A Randomized, Double-Blind Study of Paliperidone Extended-Release in Treatment of Acute Schizophrenia in Adolescents,\"",
"      <i>",
"       Biol Psychiatry",
"      </i>",
"      , 2011, 70(12):1179-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/51/36663/abstract-text/21831359/pubmed\" id=\"21831359\" target=\"_blank\">",
"        21831359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stigler KA, Mullett JE, Erickson CA, et al, \"Paliperidone for Irritability in Adolescents and Young Adults With Autistic Disorder,\"",
"      <i>",
"       Psychopharmacology (Berl)",
"      </i>",
"      , 2012, 223(2):237-45",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/51/36663/abstract-text/22549762/pubmed\" id=\"22549762\" target=\"_blank\">",
"        22549762",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87122 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-C3C4DA4C00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_51_36663=[""].join("\n");
var outline_f35_51_36663=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709193\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3981432\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5941023\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513469\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513477\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982430\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3981434\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513478\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513474\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513470\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14087817\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982388\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513471\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513490\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513472\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9838448\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982393\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513473\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982378\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3982379\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513479\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513475\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513476\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513480\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513481\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87122\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87122|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44728?source=related_link\">",
"      Paliperidone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/42/3750?source=related_link\">",
"      Paliperidone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_51_36664="Cytomegalovirus infection and disease in newborns, infants, children and adolescents";
var content_f35_51_36664=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cytomegalovirus infection and disease in newborns, infants, children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/51/36664/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/51/36664/contributors\">",
"     Gail J Demmler-Harrison, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/51/36664/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/51/36664/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/51/36664/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/51/36664/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/51/36664/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/51/36664/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) is a ubiquitous virus that commonly infects people across the spectrum of all ages, races, and ethnic groups, and those from a variety of socioeconomic, cultural, and geographic backgrounds. Although most CMV infections are asymptomatic or cause mild disease, the virus can cause serious disease in newborns and immunocompromised children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/1\">",
"     1",
"    </a>",
"    ]. Discerning which role, if any, CMV is playing in a disease process, as well as the need for treatment, can be difficult because of its ubiquity. Such decisions require a thorough knowledge of CMV virology, epidemiology, clinical manifestations, laboratory diagnosis, and indications for treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) is a member of the Herpesvirus family, along with Epstein-Barr virus (EBV); herpes simplex viruses (HSV)-1 and 2; varicella-zoster virus (VZV); and human herpesviruses (HHV)-6, -7, and -8. These viruses all share properties, including a genome of double-stranded linear DNA, a virus capsid of icosahedral symmetry, and a viral envelope [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/2\">",
"     2",
"    </a>",
"    ]. They also share the biological properties of latency and reactivation, which cause recurrent infections in the host.",
"   </p>",
"   <p>",
"    CMV is a member of the subfamily beta herpesviridae, which also contains HHV-6 and -7. CMV will replicate slowly, often taking as long as 24 hours to produce virus progeny in infected cells and several days to weeks to produce visible cytopathic effect in laboratory cell lines (",
"    <a class=\"graphic graphic_picture graphicRef81737 \" href=\"mobipreview.htm?43/16/44288\">",
"     picture 1",
"    </a>",
"    ). No distinct serotypes of CMV exist; however, strain differences can be detected by molecular analysis of DNA, providing a classification of genotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with cytomegalovirus (CMV) occurs commonly; seroepidemiologic studies have shown the prevalence of antibody to CMV is influenced by age, geography, cultural and socioeconomic status, and child-rearing practices. In developing countries, most children are infected by three years of age, whereas in developed countries, such as the United States or United Kingdom, as many as 60 to 80 percent of the population will be infected with CMV by adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Congenital infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 1 percent (0.2 to 2.5 percent) of newborns are born congenitally infected with CMV. Most of these newborns appear normal and are asymptomatic, but 5 to 15 percent of congenitally infected newborns will have symptoms at birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/4\">",
"     4",
"    </a>",
"    ]. Both maternal primary and recurrent infection during pregnancy can result in congenital infection of the infant, but the rate of transmission is far higher for mothers with primary infection (40 versus &lt;1 percent transmission). Infants born congenitally infected with CMV as a result of a primary maternal infection also are much more likely to have symptoms at birth and suffer sequelae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Perinatal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perinatal infection also can arise. Infants may be perinatally infected with CMV via contact with maternal cervicovaginal secretions during delivery or from breast milk ingestion after delivery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/21/12634?source=see_link\">",
"     \"Cytomegalovirus infection in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preterm infants appear to be at greatest risk of acquiring the virus from breast milk. One group from Germany documented CMV reactivation in 96 percent of seropositive mothers who were breast feeding their infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/5\">",
"     5",
"    </a>",
"    ]. Viral transmission occurred in 37 percent of these infants; viral DNA appeared early (median 3.5 days postpartum) in milk whey from transmitters compared with those who did not transmit the virus. Symptomatic CMV infection developed in 16 of the 33 affected infants in the cohort; very low birth weight and early transmission of virus in the postnatal period appeared to be risk factors for acquiring symptomatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Daycare",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children not congenitally or perinatally infected with CMV may acquire the virus during the toddler years or preschool years, especially if they are in contact with other children in a group daycare setting. The prevalence of active CMV shedding in the saliva and urine in daycare centers in the United States ranges from 10 to &gt;80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/7\">",
"     7",
"    </a>",
"    ]. This high prevalence, coupled with the active and often less-than-hygienic daily practices of toddlers, frequently results in horizontal transmission of the virus to both children and adult daycare center workers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Adolescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescence is another period of rapid acquisition of CMV. Sexual activity may be an important risk factor for acquiring CMV infection, and congenital CMV infection and disease can occur in infants born to teenage mothers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other modes of transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV can be transmitted among family members; a young child most frequently is the index case. Transmission can occur between siblings, from child to parent, and between parents. The sexual transmission of CMV also is well documented. The virus is shed in cervicovaginal secretions and semen. CMV antibody is associated with other indices of sexual activity, such as a history of sexually transmitted disease (STD), and CMV primary infection has been observed in young women with a recent first sexual experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, the nosocomial transmission of CMV from person to person has not been documented. Universal precautions appear adequate to prevent transmission of CMV within hospitals, and isolation of patients known to be CMV-infected is not routinely recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/11\">",
"     11",
"    </a>",
"    ]. Pregnant healthcare workers and those contemplating pregnancy are not restricted from caring for CMV-infected patients and should follow universal precautions. However, blood products and organ transplantation are sources of CMV infection in hospitals. Post-perfusion syndrome caused by CMV can be seen in newborns, especially premature infants, as well as in infants, older children, and adolescents. Immunosuppressed patients, particularly those with human immunodeficiency virus (HIV) infection, cancer, or receipt of a solid organ or bone marrow transplant, are commonly infected with CMV and at risk for developing serious disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/1,11\">",
"     1,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Congenital infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 90 percent of newborns who are congenitally infected with cytomegalovirus (CMV) are asymptomatic at birth. However, as many as 15 percent of these apparently unaffected children can experience progressive hearing loss that most often is unilateral, but occasionally may be bilateral [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Universal hearing screening programs may identify some of these otherwise asymptomatic infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/15\">",
"     15",
"    </a>",
"    ]. Hearing loss appears to be associated with increased concentrations of CMV in peripheral blood and urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Some studies have suggested that neurocognitive differences also may occur in these children, although other studies have not detected cognitive sequelae in children born with asymptomatic congenital CMV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 10 percent of congenitally infected newborns will have symptoms at birth. Somatic manifestations include: small size for gestational age, hepatosplenomegaly, petechiae and purpura of the skin, and jaundice at birth&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/19\">",
"     19",
"    </a>",
"    ]. At least two-thirds of the newborns with symptomatic congenital CMV infection will have neurologic involvement, including microcephaly, seizures, abnormal neurologic examination, and feeding difficulties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory abnormalities include: abnormal blood counts (especially thrombocytopenia), hemolytic anemia, elevated transaminases, and elevated direct and indirect serum bilirubin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/19\">",
"     19",
"    </a>",
"    ]. A wide range of abnormalities of the brain may be detected on cranial imaging (eg, unenhanced computed tomographic [CT scan]) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69239 \" href=\"mobipreview.htm?29/12/29902\">",
"     image 1",
"    </a>",
"    ). These abnormalities include periventricular leukomalacia and cystic abnormalities, periventricular calcifications (linear or punctate), ventriculomegaly, vasculitis, neuronal migration abnormalities, and hydranencephaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/12,20\">",
"     12,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ocular abnormalities, including chorioretinitis (a posterior uveitis), retinal scars, optic atrophy, and central vision loss, also may be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/13\">",
"     13",
"    </a>",
"    ]. The presence of microcephaly, intracranial calcifications, or other CT scan abnormalities plus chorioretinitis correlates with a poor neurodevelopmental outcome; the absence of these factors predicts a normal or near-normal cognitive outcome.",
"   </p>",
"   <p>",
"    Sensorineural hearing loss is detected in more than two-thirds of newborns with symptomatic congenital CMV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/4,9\">",
"     4,9",
"    </a>",
"    ]. Like that associated with asymptomatic infection, this hearing loss almost always is progressive, eventually producing severe to profound hearing loss in the affected ear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/12,20\">",
"     12,20",
"    </a>",
"    ]. Infants with hearing loss caused by congenital CMV infection or disease may be cognitively normal or they may experience cognitive delays, depending upon the degree of brain involvement experienced in utero [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Endocrinopathies, such as Graves disease and diabetes insipidus, also have been reported in congenitally infected newborns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Perinatal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perinatal infection with CMV may occur in term and preterm infants; as noted above, transmission can arise from maternal secretions, ingestion of breast milk, or from blood product transfusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/1\">",
"     1",
"    </a>",
"    ]. This infection may become apparent as early as three weeks and as late as three to six months of age. Although often asymptomatic, perinatal infection with CMV can produce a variety of clinical symptoms. A sepsis-like syndrome occurs most commonly and is associated with hepatosplenomegaly, abnormal blood counts with lymphopenia, neutropenia and thrombocytopenia, abnormal transaminases, and pneumonitis. In the German cohort cited above, sepsis-like syndrome developed in 4 of the 16 preterm infants who had symptomatic CMV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/6\">",
"     6",
"    </a>",
"    ]. These symptoms appear to be transient and to have no effect on neonatal outcome (eg, bronchopulmonary dysplasia, necrotizing enterocolitis, growth) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extremely premature infant has been identified as at risk for developing severe perinatal CMV disease; maternal sources, breast milk, and transfusions have been speculated to be origins of transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/4,6,24\">",
"     4,6,24",
"    </a>",
"    ]. Preventive measures for transmission of CMV to these vulnerable newborns have not been fully established. Most nurseries provide CMV seronegative or leukocyte-reduced blood to extremely premature infants. Methods to reduce the risk of transmission through human milk are the subject of active research in the attempt to inactivate virus yet retain the nutritional and immunologic benefits of human milk. Some nurseries provide frozen human milk. Pasteurization is another process that may reduce the transmission of CMV in human milk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acquired CMV infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most postnatally acquired CMV infections are asymptomatic in healthy children and adolescents. However, approximately 10 percent of acquired CMV infections produce symptoms. CMV can cause a mononucleosis&ndash;like syndrome; the most common manifestations are fever, fatigue, pharyngitis, adenopathy, and hepatitis. Headache, abdominal pain with diarrhea, arthralgias, and rash also may occur. Laboratory abnormalities include lymphocytosis or lymphopenia with thrombocytopenia and elevated transaminases. However, the heterophile antibody titers or monospot tests will be negative.",
"   </p>",
"   <p>",
"    CMV infection can result from person-to-person transmission of the virus from intimate contact or produce a perfusion syndrome if acquired from blood product transfusion. Unusual manifestations or complications of acquired CMV infections in healthy individuals include rare reports of pneumonitis, myopericarditis, hemolytic anemia, viral hemophagocytic syndrome, granulomatous hepatitis, Guillain-Barr&eacute; syndrome, and meningoencephalitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     CMV infections in immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunocompromised children and adolescents commonly experience CMV infection and are at risk for acquiring serious CMV disease. Infection may result from reactivation of endogenous virus, infection from the transplanted organ, or from blood product transfusion. An imbalance of increased viral activation and lack of immune surveillance commonly produces CMV disease in these patients. Risk factors for CMV disease include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/1,25\">",
"     1,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transplantation of an organ from a CMV-seropositive donor into a CMV-seronegative recipient",
"     </li>",
"     <li>",
"      Decreased T-cell function and surveillance in patients who receive immunosuppressive drugs for graft survival or who have diseases that affect T lymphocytes",
"     </li>",
"     <li>",
"      Transplantation of an organ with CMV viremia or an increased CMV viral load",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The consequences of acquired CMV infections in immunocompromised hosts include significant morbidity and mortality rates, enhanced immune suppression that favors the development of other opportunistic infections, decreased graft survival, and increased resource utilization.",
"   </p>",
"   <p>",
"    Symptoms associated with CMV disease in the immunocompromised child often are linked to the underlying disease process responsible for the immunosuppression. The most common manifestations seen in all types of patients include fever, malaise, and leukopenia. However, CMV infection in renal transplant recipients is most likely to be associated with graft loss; hepatitis and colitis occur most commonly in liver transplant recipients, pneumonitis in lung and bone marrow transplant recipients, and early myocarditis followed by late atherosclerosis in heart transplant recipients. Children with HIV and CMV co-infection may experience retinitis, colitis, and",
"    <span class=\"nowrap\">",
"     encephalitis/encephalopathy;",
"    </span>",
"    a rapid progression of HIV infection frequently occurs during infancy in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LABORATORY DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory diagnosis of cytomegalovirus (CMV) infection and disease depends upon the specific CMV disease under consideration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Congenital CMV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of congenital CMV infection or disease is accomplished by isolation of the virus in urine or saliva samples collected within the first three weeks of life. These infants often have very high titers of virus, and the culture frequently will become positive within one to three days of incubation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/4\">",
"     4",
"    </a>",
"    ]. The use of culture-enhancement centrifugation systems, such as the shell vial assay (staining for early antigen production), has been substituted for traditional cell monolayer culture in many laboratories. Detection of CMV DNA in the urine and serum of newborns also using polymerase chain reaction (PCR) techniques may be used to diagnose congenital CMV infection, but these methods are less available, more expensive, and often less reliable than is traditional cell culture or shell vial culture of the urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis by viral culture or DNA detection of the virus in amniotic fluid or by CMV IgM antibody determination of fetal blood also has been reported and may be especially useful in the symptomatic fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Serology for CMV IgG antibody determination (TORCH titers) is not helpful because most of the general population has CMV antibody, and a positive result may only reflect passive transfer of maternal antibody to the infant. The presence of CMV IgM antibody in the newborn suggests congenital infection may be present. However, confirmatory viral culture still must be performed because both false-positive and false-negative serologic results occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/4,27\">",
"     4,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28041?source=see_link\">",
"     \"Overview of TORCH infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/21/12634?source=see_link\">",
"     \"Cytomegalovirus infection in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Older children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The confirmation of an acquired CMV infection in a healthy child or adolescent is best accomplished by documenting a CMV IgG seroconversion with the presence of CMV IgM antibody. CMV cultures of the urine and saliva and blood also may be positive during the acute phase of the infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory confirmation that a CMV infection is causing disease in an immunocompromised host is difficult, and frequently requires demonstration of CMV in the end organ involved in combination with CMV viremia, CMV antigenemia, or a positive PCR for CMV DNA in the blood. Serology and urine or saliva cultures rarely are helpful in this population because most patients are seropositive and shed virus, and the presence of these positive tests are not specific for the development of disease.",
"   </p>",
"   <p>",
"    Immunocompromised patients, especially transplant recipients, often are monitored by weekly laboratory viral surveillance using surrogate markers for viremia such as antigenemia or PCR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Bone marrow transplant patients at risk for developing pneumonitis may undergo periodic bronchoalveolar lavage for CMV culture and rapid diagnostic tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/25\">",
"     25",
"    </a>",
"    ]. Because the presence of viremia or positive tests that are surrogate markers for viremia have been shown to be risk factors for development of end organ disease in immunocompromised patients, preemptive antiviral therapy often will be initiated when these markers of active infection are positive but before overt disease develops [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of asymptomatic cytomegalovirus (CMV) infections that are congenital or acquired in the normal host is not recommended. Treatment of CMV disease processes in the immunologically normal child must be individualized, as there are no clinical trials to document efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of CMV infection and disease in the immunocompromised patient definitely reduces mortality and morbidity, especially if instituted early [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/1,33\">",
"     1,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Ganciclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV disease treatment in both adults and children usually is divided into an induction phase, consisting of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/2/34848?source=see_link\">",
"     ganciclovir",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose IV every 12 hours for two to three weeks, depending upon the clinical and virologic response), followed by a maintenance phase for high-risk patients, such as bone marrow transplant recipients, patients with AIDS, or those in whom prolonged immunosuppression is anticipated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/33\">",
"     33",
"    </a>",
"    ]. Maintenance therapy usually consists of a single daily dose of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    administered every other day or five days a week, skipping the weekend. Oral ganciclovir is no longer available in the United States.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/2/34848?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    produces a reversible, dose-dependent bone marrow suppression that may manifest as leukopenia, neutropenia, anemia, or thrombocytopenia. Thus, patients receiving ganciclovir should have their blood counts monitored closely. The drug is excreted renally, and the dose should be adjusted if renal insufficiency or renal failure is present. Local infiltration of the intravenous solution also may produce local reaction, ulcers, and even scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Other regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;If clinical or virologic response is not seen, then",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/4/24646?source=see_link\">",
"     foscarnet",
"    </a>",
"    may be added to the regimen if renal function allows. Experience with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/34/14886?source=see_link\">",
"     cidofovir",
"    </a>",
"    is limited in children and the drug should be used only with extreme caution. Some experts will add hyperimmune CMV globulin to the treatment regimen in high-risk patients, but the efficacy of this approach is uncertain.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/18/21798?source=see_link\">",
"     Valganciclovir",
"    </a>",
"    , an orally available form of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/2/34848?source=see_link\">",
"     ganciclovir",
"    </a>",
"    , is another option for the treatment of CMV in solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of neonates with congenital or perinatal CMV disease remains controversial but may be considered in certain patients. Newborns who are likely to benefit immediately from antiviral therapy with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/2/34848?source=see_link\">",
"     ganciclovir",
"    </a>",
"    include those with [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Viral sepsis-like syndrome caused by CMV",
"     </li>",
"     <li>",
"      Pneumonitis or severe and refractile thrombocytopenia",
"     </li>",
"     <li>",
"      Sight-threatening retinitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Newborns who may benefit long-term from antiviral therapy include those with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sensorineural hearing loss",
"     </li>",
"     <li>",
"      Microcephaly",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Ganciclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacokinetic studies performed in newborns suggest that administering",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/2/34848?source=see_link\">",
"     ganciclovir",
"    </a>",
"    in a dose of 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose administered intravenously over the course of one hour is reasonable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/36\">",
"     36",
"    </a>",
"    ]. One report of a randomized clinical trial of ganciclovir (6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose administered intravenously for six weeks) in newborns with severe congenital CMV disease and neurologic involvement showed apparent protection against hearing loss or progression of the infection and improved head circumference growth for the first 6 to 12 months of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/37\">",
"     37",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/18/21798?source=see_link\">",
"     Valganciclovir",
"    </a>",
"    , an orally available form of ganciclovir, also has been used in the treatment of congenital CMV infection. The same systemic ganciclovir exposure can be provided, in young infants, by valganciclovir administered orally at a dose of 16",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily, but randomized clinical trial data are not yet available for valganciclovir use in infancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventing cytomegalovirus (CMV) infection is difficult because the virus is so ubiquitous and infection occurs so commonly. However, in certain circumstances, trying to prevent CMV infection is desirable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Personal protective measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hygienic precautions that have been shown to reduce the risk of family transmission of the virus can be instituted in pregnant women or those trying to become pregnant who are CMV seronegative to attempt to prevent the acquisition of primary CMV during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/41\">",
"     41",
"    </a>",
"    ]. These precautions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoiding kissing young toddlers and children on or near the mouth",
"     </li>",
"     <li>",
"      Not sharing eating or drinking utensils, drinks, or food with toddlers or young children",
"     </li>",
"     <li>",
"      Careful handwashing or using gloves after wiping noses, drool, and changing diapers",
"     </li>",
"     <li>",
"      Avoiding intimate contact during the communicable period (when there is active viral shedding from saliva, genital secretions, or semen) with a sexual partner if the partner has documented CMV mononucleosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Blood products and organ donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood products given to newborns (especially preterm infants), pregnant women, and immunocompromised patients should be from CMV seronegative donors or leukoreduced. Leukoreduction appears to be comparable to seronegative blood in preventing CMV transmission. Selection of CMV seronegative donors for organ and bone marrow transplantation, when appropriate and available, also will reduce the risk of acquiring CMV infection and disease in these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24665?source=see_link\">",
"     \"Leukoreduction to prevent complications of blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Passive immunoprophylaxis with intravenous immune globulin or CMV hyperimmune globulin may prevent acquisition of serious CMV disease in bone marrow and organ transplant recipients at high risk for acquiring CMV disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/25,43\">",
"     25,43",
"    </a>",
"    ]. Antiviral prophylaxis with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/2/34848?source=see_link\">",
"     ganciclovir",
"    </a>",
"    administered pretransplant and immediately post-transplant to recipients at high risk for CMV disease also may reduce the risk of serious CMV disease in the early post-transplant period. However, CMV infection and disease may still develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of experimental CMV vaccines currently are in clinical trials and may be helpful someday in preventing CMV disease in newborns and immunocompromised patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36664/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/10/19618?source=see_link\">",
"       \"Patient information: Cytomegalovirus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H347458443\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytomegalovirus (CMV), a member of the Herpesvirus family, is a ubiquitous virus that infects people of all ages, races, and ethnic groups. CMV can be transmitted congenitally, with a high risk of transmission for mothers with primary infection, perinatally, through contact with toddlers in the child care setting, among family members, sexually, and through blood product administration or organ transplantation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology and transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of congenital CMV infection include small size for gestational age, hepatosplenomegaly, petechiae and purpura, jaundice, neurologic findings such as microcephaly, seizures, ocular abnormalities including chorioretinitis, and sensorineural hearing loss. Most newborns with congenital CMV are asymptomatic at birth but as many as 15 percent will develop progressive hearing loss. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for CMV infections in immunocompromised hosts include transplantation of an organ from a CMV-seropositive donor into a CMV-seronegative recipient, depressed T-cell function, and transplantation of a CMV-infected organ. Clinical manifestations of infection in immunocompromised infants, children and adolescents include fever, leukopenia, and malaise with end-organ involvement such as kidney graft loss, hepatitis, pneumonitis, or myocarditis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory tools for diagnosis of CMV include virus isolation, detection of CMV antigen using PCR, and serology. Congenital CMV is diagnosed by isolation of virus within the first three weeks of life. Acquired CMV is ideally diagnosed by documenting seroconversion with presence of CMV IgM antibody. Confirmation of CMV infection in immunocompromised hosts is difficult and can require demonstration of infection in blood and an end organ. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Laboratory diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children who are immunocompromised, treatment of CMV infection is initiated with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/2/34848?source=see_link\">",
"       ganciclovir",
"      </a>",
"      given intravenously at an initial dose of 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours. The combination of intravenous immune globulin or CMV immune globulin intravenous can be synergistic in treatment of CMV pneumonia in hematopoietic stem cell recipients. Other treatment modalities include",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/4/24646?source=see_link\">",
"       foscarnet",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/18/21798?source=see_link\">",
"       valganciclovir",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neonates with symptomatic congenital CMV infection involving the central nervous system can potentially derive protection against hearing deterioration and developmental impairment from six weeks of treatment with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/2/34848?source=see_link\">",
"       ganciclovir",
"      </a>",
"      given intravenously at a dose of 6",
"      <span class=\"nowrap\">",
"       mg/kg/every",
"      </span>",
"      12 hours. Treatment should be initiated within the first month of life. The same systemic ganciclovir exposure can be provided, in young infants, by",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/18/21798?source=see_link\">",
"       valganciclovir",
"      </a>",
"      administered orally at a dose of 16",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of CMV immune globulin intravenous in combination with antiviral drugs can reduce the risk of CMV infection in organ transplant patients. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Demmler-Harrison GJ. Cytomegalovirus. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.2022.",
"    </li>",
"    <li>",
"     Mocarski ES. Cytomegaloviruses and their resplication. In: Fields Virology, 3rd ed, Fields B, Knipe D, Howley P (Eds), Lippincott-Raven, Philadelphia 1996. Vol 2, p.2447.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/3\">",
"      Walker A, Petheram SJ, Ballard L, et al. Characterization of human cytomegalovirus strains by analysis of short tandem repeat polymorphisms. J Clin Microbiol 2001; 39:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/4\">",
"      Demmler GJ. Infectious Diseases Society of America and Centers for Disease Control. Summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev Infect Dis 1991; 13:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/5\">",
"      Hamprecht K, Maschmann J, Vochem M, et al. Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet 2001; 357:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/6\">",
"      Maschmann J, Hamprecht K, Dietz K, et al. Cytomegalovirus infection of extremely low-birth weight infants via breast milk. Clin Infect Dis 2001; 33:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/7\">",
"      Adler SP. Cytomegalovirus transmission among children in day care, their mothers and caretakers. Pediatr Infect Dis J 1988; 7:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/8\">",
"      Adler SP. Cytomegalovirus and child day care. Evidence for an increased infection rate among day-care workers. N Engl J Med 1989; 321:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/9\">",
"      Istas AS, Demmler GJ, Dobbins JG, Stewart JA. Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry. Clin Infect Dis 1995; 20:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/10\">",
"      Fowler KB, Stagno S, Pass RF. Maternal age and congenital cytomegalovirus infection: screening of two diverse newborn populations, 1980-1990. J Infect Dis 1993; 168:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/11\">",
"      Demmler GJ, Yow MD, Spector SA, et al. Nosocomial cytomegalovirus infections within two hospitals caring for infants and children. J Infect Dis 1987; 156:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/12\">",
"      Noyola DE, Demmler GJ, Nelson CT, et al. Early predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection. J Pediatr 2001; 138:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/13\">",
"      Coats DK, Demmler GJ, Paysse EA, et al. Ophthalmologic findings in children with congenital cytomegalovirus infection. J AAPOS 2000; 4:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/14\">",
"      Foulon I, Naessens A, Foulon W, et al. A 10-year prospective study of sensorineural hearing loss in children with congenital cytomegalovirus infection. J Pediatr 2008; 153:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/15\">",
"      Stehel EK, Shoup AG, Owen KE, et al. Newborn hearing screening and detection of congenital cytomegalovirus infection. Pediatrics 2008; 121:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/16\">",
"      Boppana SB, Fowler KB, Pass RF, et al. Congenital cytomegalovirus infection: association between virus burden in infancy and hearing loss. J Pediatr 2005; 146:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/17\">",
"      Lanari M, Lazzarotto T, Venturi V, et al. Neonatal cytomegalovirus blood load and risk of sequelae in symptomatic and asymptomatic congenitally infected newborns. Pediatrics 2006; 117:e76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/18\">",
"      Walter S, Atkinson C, Sharland M, et al. Congenital cytomegalovirus: association between dried blood spot viral load and hearing loss. Arch Dis Child Fetal Neonatal Ed 2008; 93:F280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/19\">",
"      Kylat RI, Kelly EN, Ford-Jones EL. Clinical findings and adverse outcome in neonates with symptomatic congenital cytomegalovirus (SCCMV) infection. Eur J Pediatr 2006; 165:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/20\">",
"      Boppana SB, Fowler KB, Vaid Y, et al. Neuroradiographic findings in the newborn period and long-term outcome in children with symptomatic congenital cytomegalovirus infection. Pediatrics 1997; 99:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/21\">",
"      Williamson WD, Demmler GJ, Percy AK, Catlin FI. Progressive hearing loss in infants with asymptomatic congenital cytomegalovirus infection. Pediatrics 1992; 90:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/22\">",
"      Fowler KB, McCollister FP, Dahle AJ, et al. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr 1997; 130:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/23\">",
"      Neuberger P, Hamprecht K, Vochem M, et al. Case-control study of symptoms and neonatal outcome of human milk-transmitted cytomegalovirus infection in premature infants. J Pediatr 2006; 148:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/24\">",
"      Vochem M, Hamprecht K, Jahn G, Speer CP. Transmission of cytomegalovirus to preterm infants through breast milk. Pediatr Infect Dis J 1998; 17:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/25\">",
"      Goodrich JM, Boeckh M, Bowden R. Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 1994; 19:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/26\">",
"      Kovacs A, Schluchter M, Easley K, et al. Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 1999; 341:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/27\">",
"      Nelson CT, Istas AS, Wilkerson MK, Demmler GJ. PCR detection of cytomegalovirus DNA in serum as a diagnostic test for congenital cytomegalovirus infection. J Clin Microbiol 1995; 33:3317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/28\">",
"      Demmler GJ, Buffone GJ, Schimbor CM, May RA. Detection of cytomegalovirus in urine from newborns by using polymerase chain reaction DNA amplification. J Infect Dis 1988; 158:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/29\">",
"      Jones RN, Neale ML, Beattie B, et al. Development and application of a PCR-based method including an internal control for diagnosis of congenital cytomegalovirus infection. J Clin Microbiol 2000; 38:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/30\">",
"      Grazia Revello M, Zavattoni M, Sarasini A, et al. Prenatal diagnostic and prognostic value of human cytomegalovirus load and IgM antibody response in blood of congenitally infected fetuses. J Infect Dis 1999; 180:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/31\">",
"      van den Berg AP, Klompmaker IJ, Haagsma EB, et al. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis 1991; 164:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/32\">",
"      Weinberg A, Hodges TN, Li S, et al. Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation. J Clin Microbiol 2000; 38:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/33\">",
"      Crumpacker CS. Ganciclovir. N Engl J Med 1996; 335:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/34\">",
"      Asberg A, Rollag H, Hartmann A. Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients. Expert Opin Pharmacother 2010; 11:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/35\">",
"      Vallejo JG, Englund JA, Garcia-Prats JA, Demmler GJ. Ganciclovir treatment of steroid-associated cytomegalovirus disease in a congenitally infected neonate. Pediatr Infect Dis J 1994; 13:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/36\">",
"      Whitley RJ, Cloud G, Gruber W, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1997; 175:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/37\">",
"      Kimberlin DW, Lin CY, S&aacute;nchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003; 143:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/38\">",
"      Acosta EP, Brundage RC, King JR, et al. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin Pharmacol Ther 2007; 81:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/39\">",
"      Galli L, Novelli A, Chiappini E, et al. Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants. Pediatr Infect Dis J 2007; 26:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/40\">",
"      Lombardi G, Garofoli F, Villani P, et al. Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. Eur J Clin Microbiol Infect Dis 2009; 28:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/41\">",
"      Adler SP, Finney JW, Manganello AM, Best AM. Prevention of child-to-mother transmission of cytomegalovirus by changing behaviors: a randomized controlled trial. Pediatr Infect Dis J 1996; 15:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/42\">",
"      Demmler GJ, O'Neil GW, O'Neil JH, et al. Transmission of cytomegalovirus from husband to wife. J Infect Dis 1986; 154:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/43\">",
"      Paya CV. Prevention of cytomegalovirus disease in recipients of solid-organ transplants. Clin Infect Dis 2001; 32:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/44\">",
"      Plotkin SA. Vaccination against cytomegalovirus, the changeling demon. Pediatr Infect Dis J 1999; 18:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36664/abstract/45\">",
"      Pass RF, Dulieg&egrave; AM, Boppana S, et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 1999; 180:970.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5965 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-9843F0D5B8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_51_36664=[""].join("\n");
var outline_f35_51_36664=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H347458443\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY AND TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Congenital infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Perinatal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Daycare",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Adolescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other modes of transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Congenital infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Perinatal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acquired CMV infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CMV infections in immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LABORATORY DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Congenital CMV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Older children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Ganciclovir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Other regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Neonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Ganciclovir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Personal protective measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Blood products and organ donors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H347458443\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5965\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5965|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/12/29902\" title=\"diagnostic image 1\">",
"      Congenital CMV cranial CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5965|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/16/44288\" title=\"picture 1\">",
"      CMV focal cytopathic changes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/21/12634?source=related_link\">",
"      Cytomegalovirus infection in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28041?source=related_link\">",
"      Overview of TORCH infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/10/19618?source=related_link\">",
"      Patient information: Cytomegalovirus (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_51_36665="Etiology and evaluation of microcephaly in infants and children";
var content_f35_51_36665=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology and evaluation of microcephaly in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/51/36665/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/51/36665/contributors\">",
"     Julie A Boom, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/51/36665/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/51/36665/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/51/36665/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/51/36665/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/51/36665/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/51/36665/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/51/36665/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The measurement of head circumference (also called occipitofrontal circumference [OFC]), a direct reflection of head growth, is an important step in the evaluation of childhood growth and development. Deviations from normal head growth may be the first indication of an underlying congenital, genetic, or acquired problem (eg, congenital infection, genetic syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Many genetic conditions are associated with an abnormal pattern of head growth; the earlier these conditions are detected, the earlier appropriate treatment, services, and genetic counseling can be provided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology and evaluation of microcephaly in infants and children will be reviewed here. The etiology and evaluation of macrocephaly and the clinical genetics approach to microcephaly are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/8/17545?source=see_link\">",
"     \"A clinical genetics approach to microcephaly\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/54/3946?source=see_link&amp;anchor=H6#H6\">",
"     \"Etiology and evaluation of macrocephaly in infants and children\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL HEAD GROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal head growth in infants and children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42633?source=see_link&amp;anchor=H12#H12\">",
"     \"Normal growth patterns in infants and prepubertal children\", section on 'Head growth'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11194?source=see_link&amp;anchor=H4#H4\">",
"     \"The pediatric physical examination: HEENT\", section on 'Fontanelles'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occipitofrontal circumference (OFC) should be measured at health maintenance visits between birth and three years of age and in any child with neurologic symptoms. The measuring tape should encircle the head and include an area 1 to 2 cm above the glabella anteriorly and the most prominent portion of the occiput posteriorly (",
"    <a class=\"graphic graphic_picture graphicRef70799 \" href=\"mobipreview.htm?35/54/36707\">",
"     picture 1",
"    </a>",
"    ). Measurement of OFC in the newborn may be unreliable until the third or fourth day of life since it may be affected by caput succedaneum, cephalohematoma, or molding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/6\">",
"     6",
"    </a>",
"    ]. In older infants, the accuracy of the measurement may be affected by thick hair and deformation or hypertrophy of the cranial bone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;OFC measurements are most informative when plotted over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/7\">",
"     7",
"    </a>",
"    ]. Standards have been determined for head growth in healthy children between 0 and 18 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. Most clinicians use the standard growth curves to monitor the head growth of premature infants, with an adjustment for prematurity (ie, corrected age), until approximately 18 months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23912?source=see_link&amp;anchor=H9#H9\">",
"     \"Growth management in preterm infants\", section on 'Monitoring of growth'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18523310\">",
"    <span class=\"h3\">",
"     Head circumference charts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several standardized charts are available for monitoring head circumference. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Centers for Disease Control and Prevention (CDC) National Center for Health Statistics head circumference charts for children 0 to 36 months of age (",
"      <a class=\"external\" href=\"file://www.cdc.gov/growthcharts/cdc_charts.htm\">",
"       CDC growth charts",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_figure graphicRef80863 graphicRef59076 \" href=\"mobipreview.htm?43/35/44602\">",
"       figure 1A-B",
"      </a>",
"      ) (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?16/25/16788?source=see_link\">",
"       calculator 1",
"      </a>",
"      ). These charts are based on a nationally representative demographic sample.",
"     </li>",
"     <li>",
"      The World Health Organization (WHO) head circumference charts for children zero to five years of age (",
"      <a class=\"external\" href=\"file://www.who.int/childgrowth/standards/en/\">",
"       WHO growth standards",
"      </a>",
"      ). These charts are based on data from the Multicentre Growth Reference Study of breastfed children living under optimal environmental conditions.",
"     </li>",
"     <li>",
"      The Nellhaus head circumference charts for children 0 to 18 years of age. These charts are based on a 1968 international meta-analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/8\">",
"       8",
"      </a>",
"      ]. They are available in the full text of reference [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Fels head circumference charts for children 0 to 18 years. These charts are based on data from the Fels Longitudinal Study of 888 white children from the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/9\">",
"       9",
"      </a>",
"      ]. They are available in the full text of reference [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The United States Head Circumference Growth Reference charts for children 0 to 21 years of age. These charts combine growth reference data from the CDC, Nellhaus, the Fels Longitudinal Study, and others [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/10\">",
"       10",
"      </a>",
"      ]. They are available in the full text of reference [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Bushby charts for adults. These charts are based on data from 354 white adults (median age 40 years, range 17 to 83 years) in two British centers; OFC percentiles are related to height [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/13\">",
"       13",
"      </a>",
"      ]. Bushby charts are available in the full text of reference [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In September 2010, the CDC recommended that the WHO growth charts be used for children zero to two years (",
"    <a class=\"graphic graphic_figure graphicRef58632 graphicRef74503 \" href=\"mobipreview.htm?4/14/4327\">",
"     figure 2A-B",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?34/31/35315?source=see_link\">",
"     calculator 2",
"    </a>",
"    ), and the CDC growth charts for children older than two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical consequences of using the WHO standards for children younger than two years of age and a different standard for older children will need to be monitored over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/11\">",
"     11",
"    </a>",
"    ]. The particular chart that is chosen for young children may affect the categorization of head size, particularly at the higher percentiles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In a retrospective cohort study of 75,412 children in a primary care network, the proportion of children with OFC &gt;95",
"    <sup>",
"     th",
"    </sup>",
"    percentile was 8.6 percent with the CDC curve and 14 percent with the WHO curve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/14\">",
"     14",
"    </a>",
"    ]. The proportion of subjects with OFC &lt;5",
"    <sup>",
"     th",
"    </sup>",
"    percentile was 2.9 percent using the CDC curves and 2.3 percent using the WHO curve.",
"   </p>",
"   <p>",
"    Another potential problem is that changing from one curve to another after age two years may change the way a particular child&rsquo;s head growth is classified. The United States Head Circumference Growth Reference charts, published in 2010, address this problem but require additional validation before their use can be widely adopted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The standard growth curves are not appropriate for monitoring the head size of children with craniosynostosis, craniofacial syndromes, and children with certain medical conditions associated with microcephaly (eg, Williams syndrome). Growth curves for children with Williams syndrome are available through",
"    <a class=\"external\" href=\"file://pediatrics.aappublications.org/content/107/5/1192.full\">",
"     the American Academy of Pediatrics",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Microcephaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of microcephaly is somewhat controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Some authors define microcephaly as an occipitofrontal circumference (OFC) more than 2 standard deviations (SD) below the mean for a given age, sex, and gestation (ie, &lt;3",
"    <sup>",
"     rd",
"    </sup>",
"    percentile) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/5,7,20\">",
"     5,7,20",
"    </a>",
"    ]. Some require that the measurement be adjusted as necessary for prematurity or parental head circumference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/9,18\">",
"     9,18",
"    </a>",
"    ]. Other authors define microcephaly as an OFC more than 3 SD below the mean [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/6,21-23\">",
"     6,21-23",
"    </a>",
"    ]. Still others introduce qualifying terms: mild microcephaly or borderline microcephaly (between 2 and 3 SD below the mean), and severe microcephaly (more than 3 SD below the mean) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/24\">",
"     24",
"    </a>",
"    ]. The American Academy of Neurology (AAN) practice parameter defines microcephaly as OFC &gt;2 SD below the mean [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/19\">",
"     19",
"    </a>",
"    ]. These distinctions are somewhat related to prognosis, as described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/6,25-27\">",
"     6,25-27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Using the definition of more than 2 SD below the mean, approximately 2 percent of the general population would be considered microcephalic even though many of these individuals are simply at the low end of the population distribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/16,28\">",
"     16,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given that microcephaly is a sign rather than a diagnosis, we prefer to use the qualifying terms, defining mild microcephaly as an OFC between 2 and 3 SD below the mean and severe microcephaly as an OFC &ge;3 SD below the mean.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microcephaly is classified in a number of ways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/16-18,21\">",
"     16-18,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      By time of onset &ndash; Congenital microcephaly is present at birth or by 36 weeks' gestation. It is sometimes called \"primary microcephaly\". Postnatal microcephaly refers to failure of normal growth in a brain that was of normal size at birth. It is sometimes called \"secondary microcephaly\".",
"     </li>",
"     <li>",
"      By etiology &ndash; Genetic or environmental.",
"     </li>",
"     <li>",
"      By relation to other growth parameters &ndash; Symmetric or asymmetric. Microcephaly is considered symmetric (or proportionate) when the OFC is more than 2 to 3 SD below the mean, but proportionate to weight and length (or height) which also are below the mean [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      By association with other anomalies &ndash; Isolated (or pure) microcephaly is not associated with any other anomalies. Syndromal (or complex) microcephaly is associated with one or more additional anomalies (",
"      <a class=\"graphic graphic_table graphicRef61045 \" href=\"mobipreview.htm?24/5/24669\">",
"       table 1",
"      </a>",
"      ). These categories tend to overlap.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Microencephaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microencephaly (micrencephaly) is an abnormally small brain. Microencephaly is a neuroimaging or neuropathologic diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/29\">",
"     29",
"    </a>",
"    ]. However, because head growth is driven by brain growth, microcephaly usually implies microencephaly (except in cases of generalized craniosynostosis in which skull growth is restricted) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/17,20,22,24,29\">",
"     17,20,22,24,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although microcephaly always implies microencephaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/5\">",
"     5",
"    </a>",
"    ], the reverse is not true. Microencephaly may be present in children with normal OFC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microencephaly has two major mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lack of brain development or abnormal brain development related to a developmental insult during the time-specific period of induction and major cellular migration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/29\">",
"       29",
"      </a>",
"      ]. Primary microcephaly is thought to result from a reduction in the number of neurons generated during neurogenesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/22\">",
"       22",
"      </a>",
"      ]. The forebrain is most severely affected (eg, holoprosencephaly) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Injury or insult to a previously normal brain (sometimes called secondary microcephaly). Secondary microcephaly is thought to result from a reduction in the number of dendritic processes and synaptic connections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of genetic abnormalities and environmental insults can affect brain development, resulting in microencephaly",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    microcephaly (",
"    <a class=\"graphic graphic_table graphicRef75479 \" href=\"mobipreview.htm?16/2/16429\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Isolated microcephaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated microcephaly (\"microcephaly vera\", &ldquo;primary microcephaly&rdquo;, or \"true microcephaly\") is present at birth and uncomplicated by other anomalies. The brain has normal architecture but is small (more than 3 standard deviations [SD] below the mean) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/16\">",
"     16",
"    </a>",
"    ]. Isolated microcephaly is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/8/17545?source=see_link&amp;anchor=H838966#H838966\">",
"     \"A clinical genetics approach to microcephaly\", section on 'Primary microcephaly'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Syndromic microcephaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous syndromes have microcephaly as one of their features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/16\">",
"     16",
"    </a>",
"    ]. A complete listing or description of such syndromes is beyond the scope of this review. However, Online Mendelian Inheritance in Man (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/\">",
"     www.ncbi.nlm.nih.gov/omim/",
"    </a>",
"    ) is an online database that permits searching according to combinations of clinical features (eg, microcephaly, syndactyly, cataracts). Select microcephaly syndromes that have recognizable phenotypes are described in the table (",
"    <a class=\"graphic graphic_table graphicRef61045 \" href=\"mobipreview.htm?24/5/24669\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/16,21\">",
"     16,21",
"    </a>",
"    ]. Syndromic microcephaly is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/8/17545?source=see_link&amp;anchor=H839052#H839052\">",
"     \"A clinical genetics approach to microcephaly\", section on 'Microcephaly with dysmorphism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neuroanatomic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroanatomic abnormalities that are associated with microcephaly include neural tube defects, holoprosencephaly, atelencephaly, lissencephaly, schizencephaly, polymicrogyria, macrogyria, and fetal brain disruption sequence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neural tube defects &ndash; Encephalocele (protrusion of a portion of the cerebral hemisphere or meninges through a skull defect) or spinal neural tube defects can be associated with abnormal development of the brain and microcephaly. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/57/3991?source=see_link\">",
"       \"Primary (congenital) encephalocele\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Holoprosencephaly &ndash; Holoprosencephaly results from incomplete development and septation of the midline central nervous system structures. It may occur as an isolated abnormality in association with other brain defects, or as part of a multiple-anomalies syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/16\">",
"       16",
"      </a>",
"      ]. It is characterized by varying degrees of brain separation, hypotelorism, facial clefts, and nasal malformations (",
"      <a class=\"graphic graphic_figure graphicRef70880 \" href=\"mobipreview.htm?41/21/42322\">",
"       figure 3",
"      </a>",
"      ). The clinical manifestations range from an isolated single maxillary incisor to cebocephaly (eg, small mouth, single nostril, and close-set eyes (",
"      <a class=\"graphic graphic_picture graphicRef60138 \" href=\"mobipreview.htm?39/26/40366\">",
"       picture 2",
"      </a>",
"      )), or cyclopia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/34/44581?source=see_link&amp;anchor=H12#H12\">",
"       \"Facial clefts and holoprosencephaly\", section on 'Holoprosencephaly'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35575?source=see_link&amp;anchor=H3#H3\">",
"       \"Congenital anomalies of the nose\", section on 'Holoprosencephaly'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Atelencephaly &ndash; Atelencephaly (or aprosencephaly) is a rare brain malformation without any telencephalon derived brain structures (the cerebrum and related structures) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lissencephaly &ndash; In lissencephaly, the six cortical layers do not form normally due to impaired migration of neurons from the germinal matrix lining the ventricles. The surface of the brain appears completely or partially smooth with loss or reduction of sulci (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67398 \" href=\"mobipreview.htm?30/62/31726\">",
"       image 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/17\">",
"       17",
"      </a>",
"      ]. Lissencephaly may be caused by infection, intrauterine perfusion failure, autosomal recessive inheritance, or de novo translocations and deletions. Microcephaly develops in all patients with lissencephaly by the first year; a minority is microcephalic at birth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Schizencephaly &ndash; Schizencephaly is characterized by asymmetric infolding of cortical gray matter along the primary brain cleft in the perisylvian region (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef74979 \" href=\"mobipreview.htm?39/48/40719\">",
"       image 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Polymicrogyria &ndash; Polymicrogyria is a developmental malformation characterized by excessive gyri on the surface of the brain (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57657 \" href=\"mobipreview.htm?0/29/479\">",
"       image 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Pachygyria &ndash; Pachygyria (macrogyria) is a developmental malformation characterized by a reduction in the number of sulci of the cerebrum and is often seen in lissencephaly.",
"     </li>",
"     <li>",
"      Fetal brain disruption sequence &ndash; Fetal brain disruption sequence is characterized by severe microcephaly of prenatal onset (average occipitofrontal circumference [OFC] 5.8 standard deviations [SD] below the mean), overlapping cranial sutures, prominence of the occipital bone, and scalp rugae [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/24,32-36\">",
"       24,32-36",
"      </a>",
"      ]. It is thought to result from destruction or necrosis of the brain tissue secondary to prenatal insult (eg, vascular disruption, intrauterine infection) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hydranencephaly &ndash; Hydranencephaly is vascular insult to the brain in which fluid-filled cavities replace the cerebral hemispheres; cerebellum, midbrain, thalami, and basal ganglia are usually preserved.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Metabolic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various metabolic disorders may be associated with microcephaly, but the prevalence of metabolic disorders among children with microcephaly is low (estimated to be 1 to 5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/19\">",
"     19",
"    </a>",
"    ]. Metabolic disorders associated with microcephaly include aminoacidurias (eg, phenylketonuria [PKU]), organic acidurias (eg, methylmalonic aciduria), urea cycle disorders (eg, citrullinemia), and certain storage diseases (eg, neuronal ceroid lipofuscinosis) (",
"    <a class=\"graphic graphic_table graphicRef75479 \" href=\"mobipreview.htm?16/2/16429\">",
"     table 2",
"    </a>",
"    ). (See appropriate topic reviews). With the exception of maternal phenylketonuria, phosphoglycerate dehydrogenase deficiency, and Amish lethal microcephaly, metabolic disorders rarely present with microcephaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental factors that may result in decreased brain size include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/5,24,25,37,38\">",
"     5,24,25,37,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antenatal, perinatal, and postnatal central nervous system infections. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28041?source=see_link&amp;anchor=H650131395#H650131395\">",
"       \"Overview of TORCH infections\", section on 'Clinical features of TORCH infections'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In utero drug or toxin exposure. Characteristic features of fetal alcohol exposure include pre- and postnatal growth retardation, short palpebral fissures, flat philtrum, and thin upper lip. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/4/28746?source=see_link&amp;anchor=H13#H13\">",
"       \"Infants of mothers with substance abuse\", section on 'Fetal alcohol spectrum disorder'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypoxic-ischemic insults. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30953?source=see_link\">",
"       \"Etiology and pathogenesis of neonatal encephalopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2442?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intraventricular hemorrhage or stroke resulting in ischemic destruction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42697?source=see_link\">",
"       \"Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27690?source=see_link\">",
"       \"Stroke in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe malnutrition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Systemic disease (eg, polycystic kidneys, biliary atresia, renal failure).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55603123\">",
"    <span class=\"h2\">",
"     Postnatal microcephaly",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Overview of approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for microcephaly should be initiated when a single OFC measurement is more than 2 to 3 standard deviations (SD) below the mean or when serial measurements reveal progressive decrease in head size (ie, crossing of several major percentile lines [eg, 10",
"    <sup>",
"     th",
"    </sup>",
"    , 25",
"    <sup>",
"     th",
"    </sup>",
"    , 50",
"    <sup>",
"     th",
"    </sup>",
"    , 75",
"    <sup>",
"     th",
"    </sup>",
"    , 90",
"    <sup>",
"     th",
"    </sup>",
"    ] between health supervision visits)&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation of microcephaly includes a thorough history and physical examination of the child and parents (in consideration of familial variation in head size) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/6,7,17,19,21\">",
"     6,7,17,19,21",
"    </a>",
"    ]. Ancillary testing, which is directed by clinical findings from the history and examination, may include laboratory studies and imaging. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Diagnostic testing'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H26\">",
"     'Neuroimaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Factors that determine the need for laboratory and radiologic evaluation include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age at onset",
"     </li>",
"     <li>",
"      History of antenatal insult (infection, toxin, drug, etc) (",
"      <a class=\"graphic graphic_table graphicRef75479 \" href=\"mobipreview.htm?16/2/16429\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Associated features",
"     </li>",
"     <li>",
"      Family history",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h4\">",
"     Syndromic features or signs of metabolic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;If syndromic features (",
"    <a class=\"graphic graphic_table graphicRef61045 \" href=\"mobipreview.htm?24/5/24669\">",
"     table 1",
"    </a>",
"    ) or symptoms of metabolic disease are present, consultation with, or referral to, a clinical geneticist should be initiated to determine the appropriate diagnostic evaluation. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Diagnostic testing'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/8/17545?source=see_link&amp;anchor=H838987#H838987\">",
"     \"A clinical genetics approach to microcephaly\", section on 'Initial genetics consultation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h4\">",
"     No syndromic features",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occipitofrontal circumference (OFC) more than 3 SD below the mean &ndash; If syndromic features are absent and the OFC was more than 3 SD below the mean at birth, evaluation for congenital infection and neuroimaging are warranted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/6,21\">",
"       6,21",
"      </a>",
"      ]. Consultation with, or referral to, a specialist in pediatric infectious diseases, pediatric neurology,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pediatric radiologist may be helpful in planning the diagnostic evaluation.",
"     </li>",
"     <li>",
"      OFC 2 to 3 SD below the mean &ndash; If syndromic features are absent and the OFC is between 2 and 3 SD below the mean, measurement of parental head circumference is helpful in evaluating autosomal dominant microcephaly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Parental OFC'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h4\">",
"     Abnormal development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional evaluation (ie, neuroimaging or diagnostic testing) may be warranted in children with microcephaly and abnormal development. Testing may include genetic studies, evaluation for congenital infection, and evaluation for metabolic disease or storage disorder. Consultation with a clinical geneticist, specialist in pediatric infectious diseases, or pediatric neurology is suggested to determine the most appropriate testing strategy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the history in a child with microcephaly include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/7,16,19,21\">",
"     7,16,19,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prenatal history, particularly with respect to maternal medical problems (eg, diabetes, epilepsy, phenylketonuria [PKU]), medications, infections, tobacco, alcohol, or substance use, radiation exposure; findings of antenatal ultrasonography if it was performed.",
"     </li>",
"     <li>",
"      Birth history (eg, perinatal complications, infections, metabolic issues).",
"     </li>",
"     <li>",
"      Weight, length, and OFC at birth to establish the onset of microcephaly and to determine if it is proportionate to weight and length.",
"     </li>",
"     <li>",
"      OFC trajectory to determine whether microcephaly is static or progressive.",
"     </li>",
"     <li>",
"      History of seizures, developmental history (regression of milestones may indicate metabolic disease).",
"     </li>",
"     <li>",
"      Family history of consanguinity or similarly affected individuals. The family history should include three generations to detect recessive disorders, which may skip a generation.",
"     </li>",
"     <li>",
"      For children who were born prematurely, abnormal head ultrasonography findings. In a retrospective review of 923 preterm infants (&lt;28 weeks), microcephaly at age two years was more common among those with intraventricular hemorrhage, ventriculomegaly, or an echolucent lesion than among those with normal ultrasonography (15 to 20 versus 6 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the physical examination of the child with microcephaly include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/16,21,29\">",
"     16,21,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General appearance &ndash; Dysmorphic features may suggest a particular syndrome (",
"      <a class=\"graphic graphic_table graphicRef61045 \" href=\"mobipreview.htm?24/5/24669\">",
"       table 1",
"      </a>",
"      ). However, facial dysmorphism may be distorted by microcephaly. Congenital microcephaly is usually associated with a sloping forehead and small anterior fontanelle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      OFC &ndash; The OFC should be measured and compared with previous measurements. The severity of microcephaly should be assessed by determining the number of SD below the mean (ie, the z score). The z scores for children younger than two years can be determined by using the following calculators for the World Health Organization (WHO) OFC chart (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?34/31/35315?source=see_link\">",
"       calculator 2",
"      </a>",
"      ) and the Centers for Disease Control and Prevention (CDC) growth chart (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?16/25/16788?source=see_link\">",
"       calculator 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Weight and length trajectories &ndash; The child's weight and length (or height) should also be measured and plotted on standard curves. The weight and length percentiles should be compared with the OFC percentile. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42633?source=see_link&amp;anchor=H17#H17\">",
"       \"Normal growth patterns in infants and prepubertal children\", section on 'CDC growth charts'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Several causes of microcephaly may be associated with postnatal growth failure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      short stature (eg, autosomal recessive primary microcephaly, Seckel syndrome, Rubinstein-Taybi syndrome, fetal alcohol syndrome).",
"     </li>",
"     <li>",
"      Head &ndash; In addition to measuring the OFC, examination of the head should include assessment of the head shape. In infants, assessment of the fontanelles and palpation of the cranial sutures also should be performed.",
"      <br/>",
"      <br/>",
"      The anterior fontanelle usually closes between 10 and 24 months. Early closure can be a normal finding but also is associated with microcephaly, craniosynostosis, hyperthyroidism, or hypoparathyroidism. Persistent enlargement of the anterior fontanelle in children with microcephaly may be due to a syndrome (eg, Down syndrome, trisomy 13 or 18, 5p- [cri-du-chat], Rubinstein-Taybi) or toxins. (See appropriate topic reviews).",
"      <br/>",
"      <br/>",
"      An abnormal head shape and ridges along the suture lines are suggestive of craniosynostosis. Overriding sutures and a prominent occiput is suggestive of fetal disruption sequence. Bitemporal grooving may indicate Miller-Dieker lissencephaly syndrome (",
"      <a class=\"graphic graphic_table graphicRef61045 \" href=\"mobipreview.htm?24/5/24669\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10841?source=see_link\">",
"       \"Overview of craniosynostosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Eyes &ndash; Examination of the eyes may provide clues to intrauterine infection (eg, chorioretinitis, cataract) or metabolic disease (cataract). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=see_link&amp;anchor=H11#H11\">",
"       \"Cataract in children\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28041?source=see_link&amp;anchor=H650131395#H650131395\">",
"       \"Overview of TORCH infections\", section on 'Clinical features of TORCH infections'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oropharynx &ndash; The oropharynx should be examined for single maxillary incisor (characteristic of holoprosencephaly) and other midline defects of the eyes, nose, and palate (eg, cleft lip or palate, bifid uvula, etc).",
"     </li>",
"     <li>",
"      Skin &ndash; Examination of the skin may provide clues to intrauterine infection (eg, petechiae",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      jaundice in the newborn) or metabolic disease (eg, eczematous rash in PKU). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/58/35753?source=see_link\">",
"       \"Overview of phenylketonuria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abdomen &ndash; Hepatomegaly or splenomegaly are suggestive of congenital infection.",
"     </li>",
"     <li>",
"      Neurologic assessment &ndash; Neurologic evaluation, including assessment of tone, reflexes, and",
"      <span class=\"nowrap\">",
"       intellectual/developmental",
"      </span>",
"      ability. Children with microcephaly are at risk for cerebral palsy and",
"      <span class=\"nowrap\">",
"       intellectual/developmental",
"      </span>",
"      disability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/19\">",
"       19",
"      </a>",
"      ]. Cerebral palsy is common in children with microcephaly, and children with microcephaly are at risk for",
"      <span class=\"nowrap\">",
"       intellectual/developmental",
"      </span>",
"      disability. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29209?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical features of cerebral palsy\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5257?source=see_link&amp;anchor=H2#H2\">",
"       \"Intellectual disability (mental retardation) in children: Evaluation\", section on 'Evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Parental OFC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents' OFC measurements should be obtained if possible to assess familial variation in head size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/17\">",
"     17",
"    </a>",
"    ]. This is particularly true if the microcephaly is between 2 and 3 SD below the mean [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/21\">",
"     21",
"    </a>",
"    ]. The genetic contribution to microcephaly can be assessed by using the Weaver curve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/16,41\">",
"     16,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h4\">",
"     Weaver curve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Weaver curve helps to determine whether genetic influences contribute to a child's microcephaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/41\">",
"     41",
"    </a>",
"    ]. A standard score is calculated for the child and each of the parents using the following formula:",
"   </p>",
"   <p>",
"    &nbsp;Standard score (SS) = (OFC - mean",
"    <span class=\"nowrap\">",
"     value)/SD",
"    </span>",
"   </p>",
"   <p>",
"    The mean values and SD for age and sex are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef61299 \" href=\"mobipreview.htm?31/36/32333\">",
"     table 3",
"    </a>",
"    ). In calculating the parents' standard scores, the mean value and standard deviation for an 18-year-old should be used.",
"   </p>",
"   <p>",
"    The average of the parents' SS and the child's SS are plotted on the Weaver curve (",
"    <a class=\"graphic graphic_figure graphicRef80059 \" href=\"mobipreview.htm?29/7/29821\">",
"     figure 4",
"    </a>",
"    ). A genetic contribution to microcephaly is suggested if the child's standard score is within the range determined by the average parental score, permitting the evaluation to be tailored appropriately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic testing may be warranted in children with microcephaly and abnormal development or associated clinical findings. An evidence-based practice parameter developed by the Quality Standard Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society suggests that diagnostic evaluation be guided by the presence of prenatal versus postnatal microcephaly.&nbsp;Practitioners may find this approach a useful guide in determining the sequence of diagnostic evaluation (",
"    <a class=\"graphic graphic_algorithm graphicRef76151 \" href=\"mobipreview.htm?13/10/13487\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef55140 \" href=\"mobipreview.htm?37/30/38383\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/19\">",
"     19",
"    </a>",
"    ]. Testing may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/6,7,19,21,29\">",
"     6,7,19,21,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic studies if the child has dysmorphic features. Consultation with a clinical geneticist is suggested to determine the most appropriate testing strategy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/8/17545?source=see_link&amp;anchor=H838987#H838987\">",
"       \"A clinical genetics approach to microcephaly\", section on 'Initial genetics consultation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evaluation for congenital infection. Consultation with a specialist in pediatric infectious diseases is suggested to determine the most appropriate testing strategy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28041?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of TORCH infections\", section on 'Screening for TORCH infections'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evaluation for metabolic disease or storage disorder. This may include testing for amino- and organic acidurias, lactate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      very-long-chain fatty acids if the infant is hypotonic, or plasma 7-dehydrocholesterol if the infant has features suggestive of Smith-Lemli-Opitz syndrome (",
"      <a class=\"graphic graphic_table graphicRef61045 \" href=\"mobipreview.htm?24/5/24669\">",
"       table 1",
"      </a>",
"      ). Consultation with a clinical geneticist is suggested to determine the most appropriate testing strategy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10250?source=see_link&amp;anchor=H366024#H366024\">",
"       \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Initial evaluation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13177?source=see_link&amp;anchor=H12033830#H12033830\">",
"       \"Inborn errors of metabolism: Identifying the specific disorder\", section on 'Laboratory evaluation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7914?source=see_link\">",
"       \"Organic acidemias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ophthalmology referral. Ophthalmologic examination may provide clues to congenital infection or genetic disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging studies, which may identify structural causes of microcephaly, are most useful in microcephalic children with abnormal development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/5,19\">",
"     5,19",
"    </a>",
"    ]. Most children with symptomatic microcephaly have abnormal neuroimaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. As an example, in one study of 55 children with symptomatic microcephaly, MRI revealed abnormalities in 68 percent of the children with genetic microcephaly and 100 percent of the children with intrauterine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    postnatally acquired microcephaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/43\">",
"     43",
"    </a>",
"    ]. Migrational abnormalities were the most common findings in children with genetic microcephaly. Hydranencephaly and infarction were the most common findings in children with",
"    <span class=\"nowrap\">",
"     intrauterine/postnatally",
"    </span>",
"    acquired microcephaly.",
"   </p>",
"   <p>",
"    Neuroimaging may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CT scan of the head for intracranial calcification.",
"     </li>",
"     <li>",
"      MRI scan to delineate abnormalities in CNS architecture (eg, migration abnormalities) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/20,24,29\">",
"       20,24,29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55603463\">",
"    <span class=\"h2\">",
"     Prenatal microcephaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatally, microcephaly is diagnosed by ultrasound examination and is defined as head circumference &lt;3 standard deviations below the mean or below the 2",
"    <sup>",
"     nd",
"    </sup>",
"    percentile for gestational age (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78619 \" href=\"mobipreview.htm?0/4/74\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. The diagnosis is complicated by limitations in accuracy of head circumference measurements and inconsistency between prenatal and postnatal head circumference growth curves. Although there are reference values for fetal head circumference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/47\">",
"     47",
"    </a>",
"    ], standards have not been developed for specific populations (eg, based on sex,",
"    <span class=\"nowrap\">",
"     race/ethnicity)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approach to evaluation of prenatal microcephaly depends upon the presence of associated ultrasonographic anomalies, appropriateness of other fetal biometric parameters (eg, length of bones, abdominal circumference) in relation to gestational age, historical features (eg, consanguinity, intrauterine infection), and head circumference measurements of parents and siblings. Associated ultrasonographic anomalies may indicate syndromic microcephaly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/44/2762?source=see_link\">",
"     \"Prenatal diagnosis of CNS anomalies other than neural tube defects and ventriculomegaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional evaluation (eg, karyotype, fetal brain MRI, intrauterine infection) may be obtained if a specific diagnosis is desired to help with pregnancy management. Indications for these evaluations may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parental consanguinity",
"     </li>",
"     <li>",
"      Family members with microcephaly and stigmata of autosomal dominant conditions that include microcephaly (",
"      <a class=\"graphic graphic_table graphicRef61045 \" href=\"mobipreview.htm?24/5/24669\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other CNS and non CNS morphologic abnormalities that suggest a chromosomal disorder",
"     </li>",
"     <li>",
"      Otherwise unexplained fetal microcephaly (eg, family members with normal head circumference and fetal biometric parameters other than head circumference appropriate for gestational age)",
"     </li>",
"     <li>",
"      Signs of intrauterine infection (eg, intracranial calcifications or ascites)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The developmental outcome of prenatal microcephaly depends upon the underlying etiology and associated abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If there has been a previously affected child, prenatal assessment includes a level II (high risk) fetal sonogram at 20 weeks to assess anatomy. Repeat sonogram at 32 weeks can be obtained if repeat head measurements are desired later in pregnancy. However, severe postnatal microcephaly may not be evident on sonogram during the second trimester and may not be apparent until very late in pregnancy or even postnatally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for children with microcephaly depends upon the underlying cause. The prognosis usually is worse for children whose microcephaly is part of a wider pattern of malformation (eg, trisomy 13, trisomy 18) and for those with intrauterine infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/6,49\">",
"     6,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The severity of cognitive impairment is also generally related to the severity of microcephaly, as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 212 children with microcephaly, median intelligence quotient (IQ) decreased with decreasing occipitofrontal circumference (OFC) (median IQ 35 versus 62 in children with OFC more than 3.9 standard deviations [SD] below the mean and between 2.0 and 2.1 SD below the mean, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, IQ scores in seven-year-old children with OFC more than 3 SD below the mean were more likely to have IQ scores &lt;70 than children with OFC between 2 and 3 SD below the mean (51 versus 11 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/27\">",
"       27",
"      </a>",
"      ]. None of the children with OFC more than 3 SD below the mean had IQ scores greater than 100.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, individuals with autosomal recessive primary microcephaly, Seckel syndrome, etc, generally fare better intellectually than would be predicted from their very small head circumferences.",
"   </p>",
"   <p>",
"    Most children with postnatal-onset microcephaly have poor developmental outcome. In a longitudinal cohort of 57 children with postnatal-onset microcephaly who were followed for an average of four years, only 23 percent had a normal developmental quotient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/51/36665/abstract/51\">",
"     51",
"    </a>",
"    ]. Maintenance of postnatal growth (weight and height) was associated with more favorable developmental outcomes, independent of underlying etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Head circumference (occipitofrontal circumference [OFC]) should be measured at health maintenance visits between birth and three years of age and in any child with neurologic symptoms. OFC measurements are most informative when plotted over time. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Measurement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Microcephaly is an OFC greater than 2 standard deviations (SD) below the mean for a given age, sex, and gestation. Microcephaly is mild when the OFC is between 2 and 3 SD below the mean and severe when the OFC is greater than 3 SD below the mean. Microencephaly is an abnormally small brain. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Definitions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18523310\">",
"       'Head circumference charts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of genetic abnormalities and environmental insults can affect brain development resulting in microencephaly",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      microcephaly (",
"      <a class=\"graphic graphic_table graphicRef75479 \" href=\"mobipreview.htm?16/2/16429\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation for microcephaly should be initiated when a single OFC measurement is more than 2 to 3 SD below the mean (after confirmation that the measurement was accurate) or when serial measurements reveal progressive decrease in head size. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Overview of approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial evaluation includes a history and physical examination of the child and parents. Factors that determine the urgency and extent of the ancillary evaluation of include age at onset; history of central nervous system trauma or infection; associated symptoms, neurodevelopmental abnormalities or syndromic features (",
"      <a class=\"graphic graphic_table graphicRef61045 \" href=\"mobipreview.htm?24/5/24669\">",
"       table 1",
"      </a>",
"      ); and family history. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Overview of approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consultation with, or referral to, a clinical geneticist, pediatric neurologist, or specialist in pediatric infectious diseases can be helpful in determining the appropriate studies. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Diagnostic testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Neuroimaging'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/8/17545?source=see_link&amp;anchor=H838987#H838987\">",
"       \"A clinical genetics approach to microcephaly\", section on 'Initial genetics consultation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/1\">",
"      Stoll C. Problems in the diagnosis of fragile X syndrome in young children are still present. Am J Med Genet 2001; 100:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/2\">",
"      Zvulunov A, Weitz R, Metzker A. Neurofibromatosis type 1 in childhood: evaluation of clinical and epidemiologic features as predictive factors for severity. Clin Pediatr (Phila) 1998; 37:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/3\">",
"      Furuta T, Tabuchi A, Adachi Y, et al. Primary brain tumors in children under age 3 years. Brain Tumor Pathol 1998; 15:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/4\">",
"      Tomita T, McLone DG. Brain tumors during the first twenty-four months of life. Neurosurgery 1985; 17:913.",
"     </a>",
"    </li>",
"    <li>",
"     Nard JA. Abnormal head size and shape. In: Common &amp; Chronic Symptoms in Pediatrics, Gartner JC, Zitelli BJ (Eds), Mosby, St. Louis 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/6\">",
"      Rios A. Microcephaly. Pediatr Rev 1996; 17:386.",
"     </a>",
"    </li>",
"    <li>",
"     Fenichel GM. Disorders of cranial volume and shape. In: Clinical Pediatric Neurology: A Signs and Symptoms Approach, 5th, Elsevier Saunders, Philadelphia 2005. p.353.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/8\">",
"      Nellhaus G. Head circumference from birth to eighteen years. Practical composite international and interracial graphs. Pediatrics 1968; 41:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/9\">",
"      Roche AF, Mukherjee D, Guo SM, Moore WM. Head circumference reference data: birth to 18 years. Pediatrics 1987; 79:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/10\">",
"      Rollins JD, Collins JS, Holden KR. United States head circumference growth reference charts: birth to 21 years. J Pediatr 2010; 156:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/11\">",
"      Grummer-Strawn LM, Reinold C, Krebs NF, Centers for Disease Control and Prevention (CDC). Use of World Health Organization and CDC growth charts for children aged 0-59 months in the United States. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Nutrition American Academy of Pediatrics. Failure to thrive. In: Pediatric Nutrition Handbook, 6th, Kleinman RE (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.601.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/13\">",
"      Bushby KM, Cole T, Matthews JN, Goodship JA. Centiles for adult head circumference. Arch Dis Child 1992; 67:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/14\">",
"      Daymont C, Hwang WT, Feudtner C, Rubin D. Head-circumference distribution in a large primary care network differs from CDC and WHO curves. Pediatrics 2010; 126:e836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/15\">",
"      Wright CM, Inskip HM, Godfrey K, et al. Monitoring head size and growth using the new UK-WHO growth standard. Arch Dis Child 2011; 96:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/16\">",
"      Abuelo D. Microcephaly syndromes. Semin Pediatr Neurol 2007; 14:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/17\">",
"      Leroy JG, Fr&iacute;as JL. Nonsyndromic microcephaly: an overview. Adv Pediatr 2005; 52:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/18\">",
"      Opitz JM, Holt MC. Microcephaly: general considerations and aids to nosology. J Craniofac Genet Dev Biol 1990; 10:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/19\">",
"      Ashwal S, Michelson D, Plawner L, et al. Practice parameter: Evaluation of the child with microcephaly (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2009; 73:887.",
"     </a>",
"    </li>",
"    <li>",
"     Varma R, William, SD, Wessel HB. Neurology. In: Atlas of Pediatric Physical Diagnosis, 5th, Zitelli BJ, Davis HW (Eds), Mosby Elsevier, Philadelphia 2007. p.563.",
"    </li>",
"    <li>",
"     Firth HV, Hurst JA, Hall JG. Microcephaly. In: Oxford Desk Reference: Clinical Genetics, 1st ed, Oxford University Press, Oxford 2005. p.172.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/22\">",
"      Woods CG. Human microcephaly. Curr Opin Neurobiol 2004; 14:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/23\">",
"      Leviton A, Holmes LB, Allred EN, Vargas J. Methodologic issues in epidemiologic studies of congenital microcephaly. Early Hum Dev 2002; 69:91.",
"     </a>",
"    </li>",
"    <li>",
"     Gleeson JG, Dobyns WB, Plawner L, Ashwal S. Congenital structural defects. In: Pediatric Neurology Principles and Practice, 4th ed, Swaiman KF, Ashwal S, Ferriero DM (Eds), Mosby Elsevier, Philadelphia 2006. p.399.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/25\">",
"      Avery GB, Meneses L, Lodge A. The clinical significance of \"measurement microcephaly\". Am J Dis Child 1972; 123:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/26\">",
"      Pryor HB, Thelander H. Abnormally small head size and intellect in children. J Pediatr 1968; 73:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/27\">",
"      Dolk H. The predictive value of microcephaly during the first year of life for mental retardation at seven years. Dev Med Child Neurol 1991; 33:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/28\">",
"      Sells CJ. Microcephaly in a normal school population. Pediatrics 1977; 59:262.",
"     </a>",
"    </li>",
"    <li>",
"     Menkes JH, Sarnat HB, Flores-Sarnat L. Malformations of the central nervous system. In: Child Neurology, 7th, Menkes JH, Sarnat HB, Maria BL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.284.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/30\">",
"      Mochida GH, Walsh CA. Molecular genetics of human microcephaly. Curr Opin Neurol 2001; 14:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/31\">",
"      Garcia CA, Duncan C. Atelencephalic microcephaly. Dev Med Child Neurol 1977; 19:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/32\">",
"      Russell LJ, Weaver DD, Bull MJ, Weinbaum M. In utero brain destruction resulting in collapse of the fetal skull, microcephaly, scalp rugae, and neurologic impairment: the fetal brain disruption sequence. Am J Med Genet 1984; 17:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/33\">",
"      Vill&oacute; N, Beceiro J, Cebrero M, de Frias EG. Fetal brain disruption sequence in a newborn infant with a history of cordocentesis at 21 weeks gestation. Arch Dis Child Fetal Neonatal Ed 2001; 84:F63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/34\">",
"      B&ouml;nnemann CG, Meinecke P. Fetal brain disruption sequence: a milder variant. J Med Genet 1990; 27:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/35\">",
"      Moore CA, Weaver DD, Bull MJ. Fetal brain disruption sequence. J Pediatr 1990; 116:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/36\">",
"      Corona-Rivera JR, Corona-Rivera E, Romero-Velarde E, et al. Report and review of the fetal brain disruption sequence. Eur J Pediatr 2001; 160:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/37\">",
"      Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/38\">",
"      Spohr HL, Willms J, Steinhausen HC. Prenatal alcohol exposure and long-term developmental consequences. Lancet 1993; 341:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/39\">",
"      Skull SA, Ruben AR, Walker AC. Malnutrition and microcephaly in Australian aboriginal children. Med J Aust 1997; 166:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/40\">",
"      Krishnamoorthy KS, Kuban KC, O'Shea TM, et al. Early cranial ultrasound lesions predict microcephaly at age 2 years in preterm infants. J Child Neurol 2011; 26:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/41\">",
"      Weaver DD, Christian JC. Familial variation of head size and adjustment for parental head circumference. J Pediatr 1980; 96:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/42\">",
"      Custer DA, Vezina LG, Vaught DR, et al. Neurodevelopmental and neuroimaging correlates in nonsyndromal microcephalic children. J Dev Behav Pediatr 2000; 21:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/43\">",
"      Sugimoto T, Yasuhara A, Nishida N, et al. MRI of the head in the evaluation of microcephaly. Neuropediatrics 1993; 24:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/44\">",
"      Chervenak FA, Jeanty P, Cantraine F, et al. The diagnosis of fetal microcephaly. Am J Obstet Gynecol 1984; 149:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/45\">",
"      Chervenak FA, Rosenberg J, Brightman RC, et al. A prospective study of the accuracy of ultrasound in predicting fetal microcephaly. Obstet Gynecol 1987; 69:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/46\">",
"      Kurtz AB, Wapner RJ, Rubin CS, et al. Ultrasound criteria for in utero diagnosis of microcephaly. J Clin Ultrasound 1980; 8:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/47\">",
"      Kurmanavicius J, Wright EM, Royston P, et al. Fetal ultrasound biometry: 1. Head reference values. Br J Obstet Gynaecol 1999; 106:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/48\">",
"      Berger I. Prenatal microcephaly: can we be more accurate? J Child Neurol 2009; 24:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/49\">",
"      Deloison B, Chalouhi GE, Bernard JP, et al. Outcomes of fetuses with small head circumference on second-trimester ultrasonography. Prenat Diagn 2012; 32:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/50\">",
"      Tolmie JL, McNay M, Stephenson JB, et al. Microcephaly: genetic counselling and antenatal diagnosis after the birth of an affected child. Am J Med Genet 1987; 27:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/51/36665/abstract/51\">",
"      Rosman NP, Tarquinio DC, Datseris M, et al. Postnatal-onset microcephaly: pathogenesis, patterns of growth, and prediction of outcome. Pediatrics 2011; 127:665.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2839 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-125.39.66.147-BCDCD7344F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_51_36665=[""].join("\n");
var outline_f35_51_36665=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL HEAD GROWTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18523310\">",
"      - Head circumference charts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Microcephaly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Microencephaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Isolated microcephaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Syndromic microcephaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neuroanatomic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Metabolic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Environmental factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55603123\">",
"      Postnatal microcephaly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Overview of approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Syndromic features or signs of metabolic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      No syndromic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Abnormal development",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Parental OFC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Weaver curve",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55603463\">",
"      Prenatal microcephaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2839\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2839|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?13/10/13487\" title=\"algorithm 1\">",
"      Evaluation of congenital microcephaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?37/30/38383\" title=\"algorithm 2\">",
"      Evaluation of postnatal microcephaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2839|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?30/62/31726\" title=\"diagnostic image 1\">",
"      Fetal lissencephaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?39/48/40719\" title=\"diagnostic image 2\">",
"      Fetal schizencephaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/29/479\" title=\"diagnostic image 3\">",
"      Fetal polymicrogyria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/4/74\" title=\"diagnostic image 4\">",
"      Fetal microcephaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2839|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/55/34682\" title=\"figure 1A\">",
"      CDC head circumference-for-age boys 0 to 36 months",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/1/35866\" title=\"figure 1B\">",
"      CDC head circumference-for-age girls 0 to 36 months",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/32/33281\" title=\"figure 2A\">",
"      WHO head circumference for age boys 0 to 24 months",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/3/35889\" title=\"figure 2B\">",
"      WHO head circumference for age girls 0 to 24 months",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/21/42322\" title=\"figure 3\">",
"      Holoprosencephaly spectrum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/7/29821\" title=\"figure 4\">",
"      Weaver curve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2839|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/54/36707\" title=\"picture 1\">",
"      Head circumference measure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/26/40366\" title=\"picture 2\">",
"      Cebocephaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2839|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/5/24669\" title=\"table 1\">",
"      Syndromic microcephaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/2/16429\" title=\"table 2\">",
"      Etiology of microcephaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/36/32333\" title=\"table 3\">",
"      Weaver table",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?16/25/16788?source=related_link\" title=\"calculator 1\">",
"      Calculator: CDC/NCHS infant head circumference for age percentiles (&lt;36 months)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?34/31/35315?source=related_link\" title=\"calculator 2\">",
"      Calculator: WHO Infant Head Circumference for Age Percentiles (&lt; 24 months)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/8/17545?source=related_link\">",
"      A clinical genetics approach to microcephaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29209?source=related_link\">",
"      Clinical features of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2442?source=related_link\">",
"      Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42697?source=related_link\">",
"      Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35575?source=related_link\">",
"      Congenital anomalies of the nose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/54/3946?source=related_link\">",
"      Etiology and evaluation of macrocephaly in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30953?source=related_link\">",
"      Etiology and pathogenesis of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/34/44581?source=related_link\">",
"      Facial clefts and holoprosencephaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23912?source=related_link\">",
"      Growth management in preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13177?source=related_link\">",
"      Inborn errors of metabolism: Identifying the specific disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/4/28746?source=related_link\">",
"      Infants of mothers with substance abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5257?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42633?source=related_link\">",
"      Normal growth patterns in infants and prepubertal children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7914?source=related_link\">",
"      Organic acidemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28041?source=related_link\">",
"      Overview of TORCH infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10841?source=related_link\">",
"      Overview of craniosynostosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/58/35753?source=related_link\">",
"      Overview of phenylketonuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/44/2762?source=related_link\">",
"      Prenatal diagnosis of CNS anomalies other than neural tube defects and ventriculomegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/57/3991?source=related_link\">",
"      Primary (congenital) encephalocele",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27690?source=related_link\">",
"      Stroke in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11194?source=related_link\">",
"      The pediatric physical examination: HEENT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_51_36666="AITL arborizing blood vessels";
var content_f35_51_36666=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F86422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F86422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Angioimmunoblastic T cell lymphoma with arborizing blood vessels",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymph node biopsy shows effacement of normal architecture by arborizing blood vessels and large tumor cells with clear cytoplasm. H&amp;E, x20.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_51_36666=[""].join("\n");
var outline_f35_51_36666=null;
var title_f35_51_36667="Catastrophic APS criteria";
var content_f35_51_36667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Preliminary criteria for the classification of the catastrophic anti-phospholipid antibody syndrome (APS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Evidence of involvement of three or more organs, systems and/or tissues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Development of manifestations simultaneously or in less than a week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Confirmation by histopathology of small vessel occlusion in at least one organ or tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Laboratory confirmation of the presence of",
"antiphospholipid antibodies (lupus anticoagulant and/or anticardiolipin",
"antibodies)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Definite catastrophic APS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Requires all four criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Probable catastrophic APS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        All four criteria, except for only two organs, systems, and/or sites of tissue involvement",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        All four criteria, except for the laboratory confirmation at least",
"six weeks apart due to the early death of a patient never tested for",
"APL before the catastrophic APS",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Criteria 1, 2, and 4 above",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1, 3, and 4 and the development of a third event in more than a week but less than a month, despite anticoagulation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Asherson, RA, Cervera, R, de Groot, PG, et al. Lupus 2003; 12:530.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_51_36667=[""].join("\n");
var outline_f35_51_36667=null;
var title_f35_51_36668="Childhood diarrhea etiologies";
var content_f35_51_36668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major etiologies of childhood diarrhea in developing countries",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Etiologic agents",
"       </td>",
"       <td class=\"subtitle1\">",
"        Features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        <p>",
"         <strong>",
"          Acute watery diarrhea",
"         </strong>",
"        </p>",
"        <p>",
"         Watery stools; may contain mucous. Fever may be present.",
"        </p>",
"       </td>",
"       <td>",
"        Rotavirus",
"       </td>",
"       <td>",
"        Leading cause of gastroenteritis in children younger than 2 years.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enterotoxigenic",
"        <em>",
"         Escherichia coli",
"        </em>",
"        (ETEC)",
"       </td>",
"       <td>",
"        Leading cause of gastroenteritis in older children and adults.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Vibrio cholerae",
"        </em>",
"        O1 and O139",
"       </td>",
"       <td>",
"        Associated with endemic and epidemic disease. Vomiting and voluminous \"rice-water diarrhea\" in severe cases.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Norovirus",
"       </td>",
"       <td>",
"        Abrupt onset of vomiting and diarrhea with low grade fever.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        <p>",
"         <strong>",
"          Invasive diarrhea",
"         </strong>",
"        </p>",
"        <p>",
"         Gross blood in stool. Often associated with fever, vomiting, abdominal pain.",
"        </p>",
"       </td>",
"       <td>",
"        Shigella spp.",
"       </td>",
"       <td>",
"        Leading cause of invasive diarrhea.",
"        <em>",
"         S. dysenteriae",
"        </em>",
"        serotype I produces Shiga-toxin and is associated with epidemics of severe disease. Complications include toxic megacolon, rectal prolapse, intestinal perforation, seizures, encephalopathy and sepsis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nontyphoidal",
"        <em>",
"         Salmonella enterica",
"        </em>",
"       </td>",
"       <td>",
"        Several serotypes cause gastroenteritis. Infants, elderly, and immunocompromised at increased risk for disseminated infection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Campylobacter spp.",
"       </td>",
"       <td>",
"        Predominantly",
"        <em>",
"         C. jejuni",
"        </em>",
"        and",
"        <em>",
"         C. coli",
"        </em>",
"        . May mimic appendicitis. Complications include Guillain-Barr&eacute; syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteroinvasive",
"        <em>",
"         Escherichia coli",
"        </em>",
"        (EIEC)",
"       </td>",
"       <td>",
"        EIEC are closely related to Shigella and cause a syndrome essentially identical to shigellosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enterohemorrhagic",
"        <em>",
"         Escherichia coli",
"        </em>",
"        (EHEC)",
"       </td>",
"       <td>",
"        EHEC produce Shiga toxin identical to that produced by",
"        <em>",
"         S. dysenteriae",
"        </em>",
"        serotype I, associated with increased risk of hemolytic uremic syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Entamoeba histolytica",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         E. histolytica",
"        </em>",
"        is a protozoal organism which causes intestinal infection which may be indistinguishable from Shigella and other bacteria. Rare complications include extraintestinal infections, most commonly hepatic abscess.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_51_36668=[""].join("\n");
var outline_f35_51_36668=null;
var title_f35_51_36669="Proximal uric acid reabsorption";
var content_f35_51_36669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Uric acid reabsorption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 318px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Model for urate (Ur-) reabsorption in the proximal tubule. This process begins with urate entry into the cell via a urate--OH- exchanger that is driven by the pH gradient created by the Na+-H+ antiporter. The reabsorbed urate then leaves the cell by carrier-mediated diffusion or possibly by anion exchange with an anion such as Cl-.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_51_36669=[""].join("\n");
var outline_f35_51_36669=null;
var title_f35_51_36670="Thoracic aortic dissection on reconstructed computed tomography";
var content_f35_51_36670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thoracic aortic dissection on reconstructed computed tomography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal plane reconstruction of transverse and descending thoracic aorta showing the true (TL) and false (FL) lumens of the same patient as the previous CT.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vassilios Raptopoulos, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_51_36670=[""].join("\n");
var outline_f35_51_36670=null;
var title_f35_51_36671="Kawasaski multiple CA aneurysms";
var content_f35_51_36671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kawasaski disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 283px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Selective right coronary artery angiogram in a three-year-old boy with Kawasaki disease demonstrates multiple saccular aneurysms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_51_36671=[""].join("\n");
var outline_f35_51_36671=null;
